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Abstract 
Candida albicans and other Candida species have been highly associated with several 
opportunistic fungal infections. Their ability to develop host infections is incited by 
different determinants, being virulence factors the most highlighted. Molecular targets 
of the antifungal drugs are crucial components for determination of yeast survival. 
Ergosterol, nucleic acids and glucan are the most studied molecular targets to destroy 
Candida species, being considered the basis of the development of new antifungal 
drugs. However, increasing levels of resistant Candida species to the current antifungal 
drugs have been observed, making ineffective those agents. Thus, other therapies more 
effective and safer than the current ones, are being studied, namely the use plant of 
extracts enriched in phenolic compounds. In this sense, this manuscript provide an 
historical perspective of the opportunistic fungal infections, molecular targets of the 
current anti-Candida drugs, as well as a general description of the active principles 
present in plants, focused on the antifungal potential of whole plant extracts and isolated 
phenolic compounds, against Candida species. 
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1. Introduction 
Fungi and other microbial species are widespread in the environment, including the soil, 
plants, trees, and even in the skin and other parts of the body. Most of them are not 
dangerous, even conferring some benefits to the host, being considered as commensal 
flora. Notwithstanding, some species in face to an abnormal overgrowth, might become 
harmful to the host and, in last instance, could compromise its life (Blanco and Garcia, 
2008; Brunke and Hube, 2013). 
In the last two decades, it has been observed a considerable increase in the incidence of 
deep fungal infections, not only in hospital environments, due to the increasing 
magnitude of organ transplantations, the rise of AIDS, the use of invasive devices 
(catheters, artificial joints and valves) and in immunocompromised patients, but also in 
the rest of population (Abi-Said et al., 1997; Eggimann et al., 2003a; Fanello et al., 
2001; Kim and Sudbery, 2011; Li et al., 2006; Mayer et al., 2013; Raman et al., 2013; 
Silva et al., 2011a; Tsai et al., 2013; Wächtler et al., 2012). In parallel with this, and 
despite the advances on medical and chemical industries increased the life expectancy, 
due to the indiscriminate use of some chemical substances, it has been observed an 
increasing resistance of pathogenic microorganisms to conventional drugs, leading to 
development of other complications (Agarwal et al., 2010; Alves-Silva et al., 2013; 
Asgarpanah and Kazemivash, 2012; Asl and Hosseinzadeh, 2008; Bakkali et al., 2008; 
Kanafani and Perfect, 2008; Rana et al., 2011; Sher, 2009; Shojaii and Fard, 2012; Silva 
et al., 2011b; Singh et al., 2010). 
Currently, fungal infections are the fourth leading causes of hematogenous infections 
and the most common involved fungi are Candida species, commensal microorganisms 
present in any healthy people (Pierce, 2005; Tsai et al., 2013). Symptoms and signals of 
fungal infections are not always visible, and an evolution to a systemic infection thrives 
very slowly, mostly of times, without any mistrust by the individual infected. There are 
several causal factors that contribute to those opportunistic fungal infections, some of 
them difficult, or even impossible, to avert. Pollution, smoking, certain drugs, poor diet, 
sedentary lifestyle and stress-inducing agents are some examples of aggressors 
(Devasagayam et al., 2004). However, not only external factors increase the organisms 
vulnerability to disorders, but also genetic changes in the cells, degeneration, reduction 
of the cells functionality (characteristic of aging process); damage in white blood cells 
and attacks in other cells of the organic defense system, weak the immune system, 
leading to a decrease in the ability to respond to invading organisms (Valko et al., 
2007). 
Natural defense systems are present in living organisms, but it is necessary to consider 
that, in some conditions/situations, an external strengthening and complementation diets 
are essential (Carocho and Ferreira, 2013a; Devasagayam et al., 2004). It is an 
established fact that any unbalance affects the well-being of body and potentiates the 
growing and colonization of certain invaders, among other organic disorders. Thus, a 
balanced diet, containing all macro and micronutrients in right proportions, is crucial to 
an optimal health, which was already stated by Hippocrates, the father of modern 
medicine, nearly 2.500 years ago: “Let food be the medicine and medicine be the food”. 
There are some nutrients present in foods than can help to protect and strength the body, 
at greater or lesser degree (Devasagayam et al., 2004; Murray and Pizzorno, 1998; 
Singh et al., 2004; Valko et al., 2007).  
Since the pre-historic era, plants, and other living organisms, are used by primitive 
societies due to healing properties, being sought through botanical preparations. In fact, 
natural matrices, in particular, plants, are extremely rich sources of natural 
biomolecules. Despite, with the passage of time, their use, as prevention or treatment of 
various conditions, became secondary and recently, plants have deserved a great 
relevance for scientific researchers that have been studying their bioactive properties; 
many of those properties have been related to their richness in phenolic compounds 
(Carocho and Ferreira, 2013a; Murray and Pizzorno, 1998; Wojdylo et al., 2007). 
Therefore, in the present manuscript, the activity of phenolic extracts and compounds 
against Candida species was revised and highlighted as an alternative to current 
antifungal drugs, which failed in treatment of several opportunistic fungal infections 
related with Candida species. 
 
2. Opportunistic fungal infections 
2.1. Historical perspective 
Microorganisms are ubiquitous in the world, with a wide and fascinating variety and 
diversity. In the absence of microorganisms, the life on earth is not possible, with a 
close dependency on them. Otherwise, they are responsible for the onset of several 
diseases and disorders in the host (Amara and Shibl, 2013; Isolauri et al., 2002; Kaur et 
al., 2009). 
In particular, yeasts, which belong to a category of fungi, are part of the commensal 
flora of the healthy population. Colonization by some yeast species is beneficial to the 
host, because not only limits the growth of other opportunistic pathogenic fungi, but 
also stimulates the functioning of the immune system. However, in face to an abnormal 
overgrowth, they are able to cause a wide variety of dysfunctions/disorders to the host. 
Candida species are a good example; although they are deemed a commensal 
microorganism, living smoothly in the inner warm creases and crevices of the 
gastrointestinal (GI) tract (and vaginal tract), they are able to cause problems, mainly 
vaginal infections (Asmundsdóttir et al., 2009; Brunke and Hube, 2013; Eggimann et 
al., 2003a; McCullough et al., 1996; Tsai et al., 2013).  
During some days after birth, primarily the mucosa of GI tract and upper respiratory 
passages are colonized by those species, as well as mouth, pharynx and larynx. Apart of 
the observed biochemical variations in the last trimester of pregnancy, namely 
progesterone, estradiol and glycogen levels, associated with an increase in vaginal pH, 
which favors the emergence of these infections (Carrara et al., 2010; Vázquez-González 
et al., 2013), other clinical status increase the vulnerability to yeast infections (diabetes, 
patient’s submitted to broad-spectrum of antibiotic therapy, the use of oral 
contraceptives) (Epstein and Polsky, 1998; Geiger et al., 1995; Liu et al., 2009; Lott et 
al., 2005; Sobel, 2007; Tarry et al., 2005). Furthermore, and not least important, the 
increasing magnitude of organ transplantations, the rise of AIDS and the use of invasive 
devices (catheters, artificial joints and valves) are also major factors that contribute to 
higher patient’s susceptibility to infections in hospitals (Epstein and Polsky, 1998; Kim 
and Sudbery, 2011; Pierce, 2005; Vázquez-González et al., 2013).  
Seven Candida species are classified as having major medical importance, namely 
Candida tropicalis, Candida glabrata, Candida parapsilosis, Candida stellatoidea, 
Candida krusei and Candida kyfer, being Candida albicans the most important 
(Greenberg and Glick, 2003; McCullough et al., 1996; Silva et al., 2011a; Sullivan et 
al., 2004; Westwater et al., 2007).  
Candidiasis, the most common opportunistic yeast infection in the world, has been 
related in majority with Candida albicans. This microorganism is a causative agent of 
mouth and mucocutaneous infections, among others more complicated, such as 
septicemia, endocarditis, meningitis, and peritonitis, especially in patients with reduced 
immune function or taking antibiotic therapies (Brunke and Hube, 2013; Greenberg and 
Glick, 2003; McCullough et al., 1996). Nevertheless, in the last two decades, in face to 
the rapid increase in the incidence of opportunistic fungal infections, numerous studies 
had revealed that also other species of fungi are involved in some hospital infections, 
like Aspergillus spp., Zygomyces spp., Fusarium spp., Scedosporium spp., Cryptococcus 
spp., Trichosporon spp., Geotrichum spp., and Rhodotorula spp. (Kwamin et al., 2013; 
Martins et al., 2014; Tsai et al., 2013; Vázquez-González et al., 2013). But, C. albicans 
still counting nearly 50-90% of isolates from fungal infections, being able to cause 
serious hematogenous infections that, directly, affect the welfare of individuals 
(Vázquez-González et al., 2013). 
 
2.2. Anti-Candida targets 
Due to the high incidence of opportunistic fungal infections, namely triggered by 
Candida species, a wide variety of experimental studies have been carried out towards 
the discovery of effective treatments against these opportunistic and pathogenic 
microorganisms. Cellular morphology, physiology, and metabolism are crucial aspects 
in fungal cells survival.  
All living organisms communicate with the surrounding environment and, in the case of 
Candida cells, the communication is established through the cellular membrane. 
Quorum-sensing is considered the mechanism of microbial communication, and for C. 
albicans, the main quorum sensing molecules are farnesol, tyrosol and dodecanol. This 
mechanism is not only incited by yeast growth but also by the hyphal formation (Lu et 
al., 2006; Mayer et al., 2013; Wyk et al., 2009). One of the main functions of cellular 
membrane is to maintain cells homeostasis to ensure the protection of internal 
organelles, being the first barrier in Candida cells. In the membrane, there are a wide 
variety of components present, playing different functions. The phospholipid bilayer is a 
common membrane to all eukaryotic cells, as also proteins, carbohydrates, other lipids 
(i.e. sterols, fatty acids, glycerol and esters) and even association of those substances. In 
the case of fungal cells, such as Candida species, ergosterol is the specific and most 
abundant sterol. Those molecules play important roles in the maintenance of integrity 
and fluidity of the membrane, acting as secondary messenger in the signal development 
in order to warrant the proper cell function (i.e. growth, division and reproduction). 
Thus, ergosterol is considered the main target of antifungal drugs (Ghannoum and Rice, 
1999; Kanafani and Perfect, 2008; White et al., 1998).  
Chemical substances could act by three main different ways in Candida cells: in the 
ergosterol biosynthesis (i.e. azoles) (Ghannoum and Rice, 1999; Kanafani and Perfect, 
2008; Lamb et al., 1999; Lupetti et al., 2002; Sanglard, 2002); interacting with 
ergosterol and intercalating between membrane (i.e. polyenes) (Ghannoum and Rice, 
1999; Kanafani and Perfect, 2008; Kontoyiannis and Lewis, 2002); or even causing 
ergosterol depletion (i.e. allylamides) (Kanafani and Perfect, 2008; Kontoyiannis and 
Lewis, 2002; White et al., 1998).  
Unfortunately, in the last years, it has been observed an increasing drug resistance to 
those classes of antifungal agents, being ineffective even in higher doses. Some 
virulence mechanisms have been studied, not only to explain the increasing rates of 
antifungal drugs resistance, but also to discover/create new and promising antifungal 
strategies. So far, the most frequent virulence mechanism associated with Candida 
species infections is the ability of adaptation to a wide variety of habitats, commonly 
known as morphological transition. Notwithstanding, other factors, as the ability for 
biofilm formation, the secretion of hydrolytic enzymes (such as proteases and 
phospholipases), and the expression of adhesins and invasins linked with the dimorphic 
phases and phenotypic switching, have been associated with Candida species infections 
(Mayer et al., 2013; Tsai et al., 2013).  
In this sense, different molecular targets needs to be studied as also more effective and 
selective compounds against the fungal cell wall; compounds to inhibit nucleic acids, to 
affect the plasma membrane, ergosterol, phospholipid, sphingolipid and protein 
biosynthesis; intermediates of the metabolism of nucleic acids and amino acids; 
compounds that affect efflux pumps, proton ATPases and other enzymes. The study of 
the fungal virulence factors and involved genes on antifungal resistance, among other 
important biological components with a direct interference on drug resistance, is crucial 
(Franz et al., 1998; Kanafani and Perfect, 2008; Lupetti et al., 2003; Mayer et al., 2013; 
Noël, 2012; Perlin, 2014; Sangamwar et al., 2008; Sanglard and Odds, 2002; White et 
al., 2002, 1998). Mayer et al. (2013) quoted polymorphism, secretion of hydrolases; pH 
sensing and regulation; metabolic adaptation; environmental stress response; heat shock 
proteins and small heat shock proteins, and metal acquisition as the most important 
virulence factors and fitness attributes, while Lewis et al. (2012) proposed that the 
inhibition of macrophage cell division or arrest of the host macrophages to confine the 
pathogens, is another virulence attribute of Candida species, in particular C. albicans. 
 
2.3. Current anti-Candida drugs 
Currently, there are five main classes of antifungal agents widely used at a medical level 
against the major fungal pathogens, including Candida species: polyenes, azoles, 
allylamines/thiocarbamates, fluoropyramidines and echinocandins (Maurya et al., 
2013).  
Azoles, polyenes and allylamine/thiocarbamates act, direct or indirectly, in the 
ergosterol present in all Candida species (Kontoyiannis and Lewis, 2002; Lupetti et al., 
2003). 
Polyenes comprise a class of antifungal agents that affect cellular membranes 
containing ergosterol. These agents present amphipathic properties which allow their 
intercalation between membranes containing ergosterol, forming channels that favor the 
ionic unbalance and destroy the proton gradient (Ghannoum and Rice, 1999). Nystatin 
and amphothericin-B are the most common used polyenes (Eggimann et al., 2003b). 
Nevertheless, not only primary but also secondary resistance of Candida species, 
namely C. albicans, C. lusitanea, C. guilliermondii and C. glabrata, have been observed 
(Ghannoum and Rice, 1999; Kontoyiannis and Lewis, 2002; White et al., 1998).  
Azoles are another class of antifungal agents in which the target is over again 
ergosterol, but in this case affects its biosynthesis. Firstly introduced during the 1980s 
and used by oral administration, to treat oropharyngeal candidiasis in patients with 
VIH+, they act as inhibitors of sterol 14α-demethylation. The remotion of the C32-
methyl group at a 14α- from precursor sterols, catalyzed by a microsomal cytochrome 
P450 monooxygenase, affect the main sterol present on fungal cells membranes: 
Erg11p, a lanosterol 14-alpha-demethylase. Miconazole and econazole were the original 
used azole compounds, followed by ketoconazole, fluconazole and itraconazole 
(Eggimann et al., 2003b; Ghannoum and Rice, 1999; Sardi et al., 2013). However, and 
despite during several years those drugs presented a great efficacy as antifungal agents, 
resulting in a widespread use, currently it is being observed an increasing emergence of 
Candida species-resistance (namely C. albicans, C. glabrata, C. parapsilosis, C. krusei 
and C. lusitaniae) (Develoux and Bretagne, 2005; Noël, 2012; Vázquez-González et al., 
2013).  
Allylamines (i.e. naftifine and terbinafine) and thiocarbamates (i.e. tolnaftate and 
tolciclate) are the third class of antifungal agents that interact with ergosterol. But, in 
this case, they act as inhibitors of squalene epoxidase, blocking the conversion of 
squalene into 2,3-oxidosqualene, that result in ergosterol depletion and accumulation of 
toxic sterols. It was shown that the increasing of the squalene levels is toxic, leading to 
cell membrane permeability and then disrupting the cellular organization (Ghannoum 
and Rice, 1999; White et al., 1998). However, this class of antifungal drugs presents a 
weak activity against the most frequent Candida species, being only active against 
dermatophytes (Kontoyiannis and Lewis, 2002; Sanglard, 2002). 
On the other hand, fluoropyramidines and echinocandins act differently from the 
previous drugs; the first act as inhibitor of nucleic acids, while the second as inhibitor of 
the glucan synthesis and, therefore, are effective against Candida biofilm cells 
(Kontoyiannis and Lewis, 2002; Pereira Gonzales and Maisch, 2012). 
Fluoropyrimidines, namely 5-fluorocytosine (5FC), is a fluorinated pyrimidine that 
impairs nucleic acid biosynthesis due to the formation of toxic fluorinated pyrimidine 
antimetabolites. A permease enzyme aids 5FC to enter on fungal cells, where it is 
converted into 5-fluorouracil (5FU), catalyzed by the cytosine deaminase. After this, 
5FU is converted into 5-fluorouridylic acid (FUMP) and, then, phosphorylated and 
incorporated into RNA, leading to a disruption of protein synthesis. Another mechanism 
of action of 5FU, results of its conversion into 5-fluorodeoxyuridine monophosphate, a 
potent inhibitor of the enzyme involved in DNA synthesis and nuclear division 
(Waldorf and Polak, 1983). There are some studies that refer an increasing resistance to 
5FC (Ghannoum and Rice, 1999; Gubbins and Anaissie, 2009; Liu et al., 2009; Souza et 
al., 2010), and despite several mechanisms of action responsible for 5FC resistance are 
still not established, they could be related with losses of permease activity or decrease 
of enzymatic activity responsible for the conversion of 5FC into FMUP. This process 
was observed in C. glabrata, while mutational losses of one of the pyrimidine salvage 
enzymes and decrease in UPRTase in a gene dose-dependent manner were observed in 
C. albicans strains, resistant to 5FC (Ghannoum and Rice, 1999). 
Lastly, echinocandins (i.e. caspofungin, anidulofungin, and micafungin) are the latest 
and, at the same time, the first new class of antifungal drugs. The main target of this 
drug is the fungal cell wall, acting as inhibitors of the α-1,3-D-glucan biosynthesis by 
blocking of β-1,3-D-glucan synthase (Perlin, 2014; Sanglard and Odds, 2002). Despite a 
higher level of efficiency associated to this class of antifungal drugs, exerting rapid 
fungicidal effects against Candida species, including azole-resistance species 
(Kontoyiannis and Lewis, 2002), in the last years, it has been observed an increasing 
level of resistance, namely for C. albicans, C. glabrata, C. krusei and C. parapsilosis 
(Kanafani and Perfect, 2008; Perlin, 2009). The involved resistance mechanisms were 
not completely elucidated and other are still unknown; however, drug tolerance 
conferred by adaptive cellular physiology to the environmental stress, as well as genetic 
mutations and amino acids substitutions are the main supposed contributors associated 
with Candida species echinocandin-resistant (Perlin, 2009).  
Nevertheless, new perspectives of development of new orally effective drugs are open 
and different experiments have been made (Kanafani and Perfect, 2008; Perlin, 2014, 
2009; Sanglard, 2002). So, considering all the advances on antifungal drugs research, it 
is necessary to take into account the safety, tolerability, efficacy, toxicity and, even side 
effects of these substances/chemical molecules. In this sense, other alternatives safer 
than the current antifungal drugs are necessary. 
 
3. Active principles of plants 
3.1. Plants as a rich source of bioactive compounds 
Plants have been used for several generations in traditional herbal medicine, as first 
choice treatment. The first civilizations established the therapeutic potential of plants 
taking into account the more or less prominent effects observed in the body. They also 
observed that certain plants evidenced toxic effects according to the dose. However, 
they did not know the reasons that provided those effects, as well as, the nature of plant 
constituents. Thus, much of the knowledge was empirical, passing from generation to 
generation, but lacking of a solid foundation of the use and prescription, mostly due to 
the low literacy and written information (Halberstein, 2005; Murray and Pizzorno, 
1998; Petrovska, 2012). 
Currently, it is well recognized that hundreds of biological active chemical compounds 
are present, in each plant, working in synergism, and conferring a broad variety of 
bioactivities, being subject of an increasing scientific interest. More and more, people 
worldwide use medicinal plants as first priority to maintain a good health, to prevent or 
even treat some health conditions. Linked to this, some studies have been conducted, 
using a wide variety of plants, towards the identification of bioactive molecules, their 
properties and mechanisms of action (Agarwal et al., 2010; Alves-Silva et al., 2013; 
Asgarpanah and Kazemivash, 2012; Asl and Hosseinzadeh, 2008; Bakkali et al., 2008; 
Kanafani and Perfect, 2008; Rana et al., 2011; Sher, 2009; Shojaii and Fard, 2012; Silva 
et al., 2011b; Singh et al., 2010). In fact, natural matrices, in particular, plants, are 
extremely rich sources of biomolecules that have sparked an increasing interest for 
scientific researchers, in different areas of knowledge. Until now, several chemical 
compounds have been identified, but only a few properties have been clarified, with 
many remaining undefined. Nevertheless, many compounds are still unknown, as also 
the synergic interactions among them (Carocho and Ferreira, 2013a; Choudhary and 
Atta-ur-Rahmant, 1999; Devasagayam et al., 2004; Rubió et al., 2013). 
It is truly believed that the biologically active chemical compounds present in plants act 
synergistically and confer, both direct and indirect effects, to the human body. The 
direct impact is commonly due to their phytopharmacological action, while the indirect 
impact is linked to the simultaneous interaction with other plants or drugs. Furthermore, 
it should be highlighted that, the fact that one plant from a particular genus contains a 
specific chemical composition and a significant medicinal value does not mean that all 
the other plants from the same genus had the same value. Even some studies report that 
the same species, but with different origins might have considerable differences on 
chemical composition and, therefore, a different efficacy and potency in the bioactivity 
(Farhat et al., 2009, 2013; Ghasemi Pirbalouti et al., 2013; Papageorgiou et al., 2008; 
Politeo et al., 2006). 
In the modern medical classification, a plant acquire the “medicinal” status when it 
presents several pharmacologically active compounds, making possible its use at a 
therapeutic level, conferring not only benefits in the treatment of some conditions, but 
also in prevention/prophylaxis (Balch, 2006; Murray, 2004; Murray and Pizzorno, 
1998). Notwithstanding, other chemical compounds present in trace amounts, could 
influence the action of the main molecules, which explains the higher potential of using 
the whole natural matrix instead of an isolate chemical compound (Ettefagh et al., 2011; 
Junio et al., 2011). 
Thus, it is very important to provide a correct and complete characterization of the 
bioactive compounds present in medicinal plants, in order to complement and unify the 
prescriptions and, at the same time, to establish the amount/dosage of active principles 
needed to treat/avert various health problems. Currently, due to the advances of the 
analytical methods, it was possible to elucidate the structure of thousands of 
phytochemicals, either primary or secondary metabolites (Figure 1).  
 
3.2. Primary metabolites 
Primary metabolites comprise the organic compounds derived from the primary 
metabolism of plants; they are often concentrated in seeds and/or vegetative organs and 
play an important role in the physiological development and basic cell metabolism. In 
general, these compounds are not limited to the plant kingdom, being even used in 
several biosynthetic pathways (Nelson and Cox, 2000).  
Higher plants are able to synthetize organic compounds and produce oxygen from the 
light, water and carbon dioxide, which are the main energetic and food sources for 
animals. Furthermore, these same organic compounds are also an energetic source for 
biosynthetic organisms. This process, in which autotrophic organisms produce organic 
compounds according to their needs, is commonly known as photosynthesis: light phase 
and dark phase. Organic compounds are synthetized in the dark phase, through some 
biosynthetic pathways (Nelson and Cox, 2000). Proteins, lipids, carbohydrates and 
chlorophyll are the main compounds derived from the primary metabolism (Figure 1). 
Besides many other physiological functions, proteins and even some free amino acids 
are considered crucial transport elements of a wide variety of molecules; integrate the 
genetic material binding to nucleic acids; include enzymes; play an important reserve 
role and confer high protection against invaders (Nelson and Cox, 2000; Proença da 
Cunha et al., 2010, 2012). On the other hand, lipids, commonly defined as water 
insoluble compounds but soluble in organic solvents, play important organic benefits as 
structural components of cellular membranes; energetic reserve; protective function; 
hormonal regulators and synthesizers of inflammatory immunomodulators (eicosanoids: 
prostaglandins, thromboxanes and leukotrienes), among other crucial functions in living 
organisms (Campos, 2008; Nelson and Cox, 2000). 
Carbohydrates, or glycids, represent the basis of dietary food of a majority of living 
organisms. According to the length and the type of glycosidic linkages, these molecules 
play different biological properties and have innumerous applications. One of the most 
common is their energetic cellular reservoir function, being accumulated in the main 
reserve organs of plants – seeds, grains and tubers, as well as leaves. The latest have a 
limited storage capacity (Campos, 2008; Nelson and Cox, 2000; Proença da Cunha et 
al., 2010). 
Lastly, chlorophyll, a green pigment mainly present in the higher plant protoplasts, but 
also in red algae and purple bacteria, essentially exerts functions of photosynthetic 
pigments. Despite the existence of two types of chlorophyll, a and b, both of them are 
involved in organic compounds synthesis and, therefore, in the primary function of 
plants: nutrition (Campos, 2008; Nelson and Cox, 2000).  
In fact, primary metabolites are much more than merely macronutrients. Some of the 
bioactive properties reported for plants, such as antioxidant, antimicrobial, anti-
inflammatory, and antitumor activities, have been related with primary metabolites, 
mainly lipids (polyunsaturated fatty acids, sterols), proteins, carotenoids, vitamins and 
carbohydrates (polysaccharides and glycosides) (Ksouri et al., 2012).  
 
3.3. Secondary metabolites 
Secondary metabolites are organic compounds that derived from the primary 
metabolites of plants. It is well established that these metabolites play specialized 
functions in a wide variety of living organisms, being even considered as biologically 
active compounds. They are renowned as possess higher value than the primary 
metabolites, in relation to the life expectancy, wellbeing and even to prevent/avert some 
diseases/disorders (Nelson and Cox, 2000; Rubió et al., 2013). 
Terpenes are a class of secondary metabolites formed by several isoprene units, i.e. 
several combinations of 5-carbon-base (C5). Different combinations of the isoprene 
units originate structurally and functionally different classes of terpenes (Rubió et al., 
2013). Thus, they could occur as monoterpenes (C10), diterpenes (C20), triterpenes 
(C30), tetraterpenes (C40), but also hemiterpenes (C5) and sesquiterpenes (C15). 
Monoterpenes and diterpenes are the main classes of terpenes present on herbs and 
spices. Furthermore, these compounds have important biological activities, including 
antimicrobial properties against a wide variety of pathogens such as Candida species 
(Alves et al., 2013; Rubió et al., 2013; Saleem et al., 2010). 
Steroids are secondary metabolites derived from the tetracyclic triterpenes (C30), 
composed by isoprenoid C5 units derived from isopentenyl (3-methylbut-3-en-l-yl) 
pyrophosphate, and presenting a characteristic branched chain structure. Stigmasterol 
has been reported as one of the most abundant steroids in plant oils. These compounds 
are commonly highly degraded into other products, namely steroid hormones, that play 
important organic functions (Carocho and Ferreira, 2013b; Nelson and Cox, 2000). 
Moreover, the antimicrobial activity of steroids has also been described, including the 
antifungal properties against some pathogens such as Candida species (Alves et al., 
2013; Saleem et al., 2010; Sanglard, 2002). One of the proposed mechanisms of action 
is their ability to disrupt membrane integrity (Saleem et al., 2010), but others remain 
unclear and even unknown. 
Alkaloids comprise a diverse group of heterocyclic nitrogen substances, being 
commonly considered high toxic molecules that play an important defensive role, but 
reflecting a general biological principle of poisonous plants (Inbaraj et al., 2001, 2006; 
Sertel et al., 2011). Nevertheless, in some situations, their toxicity is benefic; for 
example, Sertel et al. (2011) reported that vinblastine, vincristine (from Catharanthus 
roseus, formerly: Vinca rosea) and semisynthetic vindesine and vinorelbine, presented 
high cytotoxicity against cancer cells, highlighting the potential of these dimeric indole 
alkaloids for cancer, leukemia and lymphomas treatments. The efficacy of alkaloids 
against bacteria, parasites, dermatophytes and fungi, including Candida species, has 
also been described (Ali-Shtayeh and Ghdeib, 1999; Arif et al., 2011, 2009; Carocho 
and Ferreira, 2013b; Dzoyem et al., 2014; Rose, 1999; Sher, 2009; Silva and Fernandes 
Júnior, 2010; Wyk et al., 2009; Xie et al., 2012). The intercalation into cell wall and/or 
DNA is considered one of the main described mechanisms of bioactive action of 
alkaloids (Silva and Fernandes Júnior, 2010). 
Phenolic compounds constitute a major class of plant secondary metabolites being 
broadly distributed, with more than 8000 phenolic structures currently identified. These 
compounds can contain one or more aromatic rings with one or more hydroxyl groups 
(Dai and Mumper, 2010). In fact, the term “phenolic” or “polyphenol” can be 
chemically defined as a substance which possesses an aromatic ring bearing at least one 
(phenol) or more (polyphenol) hydroxyl substituent, including functional derivatives 
(esters, methyl ethers, glycosides, etc.), ranging from simple molecules, such as 
phenolic acids, to high complex structures, such as tannins (Dai and Mumper, 2010; 
Santos-Buelga et al., 2012). In the modern classification, the broad category of 
phenolics is divided into several groups, according to the number of phenol subunits 
present: polyphenols and simple phenols. Thus, polyphenols possessing at least two 
phenol subunits are classified as flavonoids, while those compounds which possess 
three or more phenol subunits are included in tannins (hydrolysable and non-
hydrolysable) (Giada, 2013; Robbins, 2003). Phenolic acids, flavonoids and tannins are 
the most common, being stilbenes and lignans less common (Dai and Mumper, 2010). 
Curiously, these classes of phenolic compounds are currently the main subjects of 
scientific researches. But, beyond these, other phenolic compounds, like chalcones, 
coumarins, xanthones and lignins, are also present in natural matrices (Figure 2). 
Several researchers have demonstrated the antioxidant potential of phenolic compounds 
(Çekiç et al., 2013; Rice-Evans et al., 1996; Walch et al., 2011), but currently other 
bioactive properties have also been studied. Curiously, some of these biological 
properties are directly linked to the antioxidant activity. It is a fact, that the chemical 
structure of phenolic compounds determine their properties as well as mechanism of 
action, being conferred by different ways (Giada, 2013). Nevertheless, and not less 
important, is the fact that despite Reactive Oxygen and Nitrogen Species (ROS/RNS) at 
physiological concentrations may be required for normal cell functioning and to play an 
important role in plant and animal evolutions, these species are able to attack biological 
macromolecules (e.g., cellular DNA), causing a wide variety of cellular damages, 
disorders and even diseases; to disestablish of the defense systems increasing the 
vulnerability to infections by pathogens, parasites and other invaders (Carocho and 
Ferreira, 2013a; Çekiç et al., 2013; Chaturvedi and Beal, 2013; Devasagayam et al., 
2004; Valko et al., 2007).  
 
4. Activity of phenolic extracts/compounds against Candida species 
4.1. The use of phenolic extracts against Candida species 
Several studies have been performed in order to evaluate the antifungal potential of 
polar extracts from plant origin, which are enriched in phenolic compounds, such as 
acetone (Table 1), aqueous (Table 2), ethanolic (Table 3), methanol-dichloromethane 
(Table 4), methanolic (Table 5), hydroalcoholic (methanol: or ethanol: water mixtures) 
(Table 6), DMSO, diethyl ether and ethyl acetate extracts, and tinctures (Table 7). The 
aqueous extracts were the most studied preparations, followed by methanolic and 
ethanolic extracts. 
Different techniques/assays have been used for that purpose. Agar disc diffusion and 
broth dilution (microdilution and macrodilution) methods are the most commonly used, 
being, normally, performed according to the Clinical and Laboratory Standards Institute 
(CLSI), with some modifications. Both of them are considered antimicrobial 
susceptibility tests, expressing the results as halo inhibition zones or minimal inhibitory 
(MIC) and minimal fungicidal (MFC) concentrations, respectively. The most tested 
Candida species were C. albicans, C. tropicalis, C. krusei, C. glabrata, C. parapsilosis, 
C. lusitaniae and C. guilliermondii, being considered the main species associated to 
opportunistic fungal infections (Vázquez-González et al., 2013). 
In general, the plant extracts obtained using methanol and water, as solvent extraction, 
and mixtures of the previous (hydroalcoholic extracts) were more effective against 
Candida species than the other extracts prepared with a unique solvent. Thus, the 
methanol (Table 5), aqueous (Table 2) and hydroalcoholic extracts (ethanol: water and 
methanol: water mixtures) (Table 6) presented lower MICs than the extracts obtained 
with acetone (Table 1), methanol-dichloromethane (Table 4) ethanol (Table 3) or other 
extracts (Table 7). For example, hydroalcoholic extracts of Cassia fistula (MIC=0.025 
mg/mL), Emblica officinalis (MIC=0.1024 mg/mL), Glycyrrhiza glabra (MIC=0.512 
mg/mL) and Punica granatum (MIC=0.0039 mg/mL) presented a higher antifungal 
effect, against C. albicans, than the extracts of the same plant species prepared with a 
single solvent. The only exceptions were the aqueous extracts of Sapindus saponaria 
(MIC=0.16 mg/mL), against C. parapsilosis, and Syzygium aromaticum 
(MIC=0.003125 mg/mL), against C. tropicalis, that gave a higher effect than its 
hydroalcoholic extracts, and the methanolic extract of Salvia officinalis (MIC=0.16 
mg/mL) that evidenced a higher antifungal potential, against C. tropicalis, than the 
hydroalcoholic (MIC=1.25 mg/mL) and aqueous (MIC=1.25 mg/mL) extracts. 
Notwithstanding, the number of studies that report antifungal properties of 
hydroalcoholic extracts is lower than the studies using methanol, ethanol or water. 
Comparing the antifungal potential of the extracts prepared with a unique solvent, the 
methanolic extracts (Table 5) showed the lowest MICs for the majority of the Candida 
species, followed by aqueous (Table 2) and ethanolic (Table 3) extracts. In particular, 
Adiantum capillus veneris, Artemisia herba-alba, Capparis spinosa, Eucalyptus 
sideroxylon, E. torquata, Glycyrrhiza glabra, Laurus nobilis, Pimpinella anisum and 
Salvia officinalis methanolic extracts showed higher antifungal potential than their 
aqueous and ethanolic extracts. On the other hand, Acorus calamus, Funtumia elastica, 
Hyssopus officinalis subsp. pilifer, Murraya koenigii, Ribes nigrum and Zingiber 
officinalis aqueous extracts evidenced most pronounced antifungal effects than their 
ethanolic and methanolic extracts. Allium sativum, Aloe barbadensis, Aloe excelsa, 
Cinnamomum spp. and Solanum nigrum aqueous and ethanolic extracts evidenced 
similar potential against Candida species. Lastly, Camellia sinensis, Cassia alata, 
Mallotus oppositifolius, Morinda morindoides, Origanum vulgare, Plantago media, 
Punica granatum, Quercus infectoria, Rhus angustifolia, Sclerocarya birrea and 
Thymus kotschyana ethanolic extracts evidenced higher antifungal potential than 
aqueous and methanolic extracts.  
In specific plant species, the tendency described was modified. For example, the 
methanol-dichloromethane extract of Andrographis paniculata showed a higher 
antifungal potential than their ethanolic and methanolic extracts; ethanol, acetone, 
diethyl ether and ethyl acetate extracts of Origanum vulgare, as well as aqueous and 
ethyl acetate extracts of Hyssopus officinalis subsp. Pilifer and aqueous and 
hydroalcoholic extracts of Salvia officinalis showed similar antifungal effects. 
Furthermore, Crossandra infundibuliformis ethyl acetate and methanol extracts showed 
similar effects, whereas Gonzalagunia rosea and Montanoa methanolic extracts showed 
higher antifungal potential than the corresponding methanol: dichloromethane extracts; 
the acetone extract of Paullinia cupana seems to be more effective than the ethanolic 
extract against C. albicans, but due to the differences in the units used to express the 
results, it is difficult to compare both values.  
Analysing the antifungal activity against specific Candida species, hydroalcoholic 
extracts showed the most pronounced properties against C. albicans, followed by 
methanolic and methanol-dichloromethane extracts. Punica granatum hydroalcoholic 
(ethanol:water, 50:50 v/v) extract revealed the highest antifungal activity (MIC = 
0.0039 mg/mL). In general, methanolic extracts followed by aqueous and 
hydroalcoholic extracts, showed a higher antifungal potential against C. glabrata than 
the ethanolic and methanol-dichloromethane extracts. Dorstenia turbinata (0.039 
mg/mL) and Thymbra spicata (0.01 mg/mL) methanolic extracts evidenced the most 
pronounced effects. For C. guilliermondii, the hydroalcoholic extract of Syzygium 
aromaticum (MICs = 0.05 mg/mL) was the most effective preparations, but Punica 
granatum ethanolic extract (MIC = 0.125 mg/mL) also evidenced a lower MIC value. 
For C. krusei, the methanolic extracts were the most efficient plant extract preparations, 
followed by ethanolic and aqueous extracts. Thymbra spicata (MIC = 0.01 mg/mL) and 
Laurus nobilis (MIC = 0.07 mg/mL) comprises the methanolic extracts that evidenced 
highest antifungal activity against C. krusei. Concerning C. lusitaniae, aqueous extracts 
presented the highest antifungal potential, followed by ethanolic, methanol-
dichloromethane and ethyl acetate extracts. Epilobium augustifolium aqueous extract 
(MIC = 0.05 mg/mL) revealed to be the best against C. lusitaniae. On the other hand, to 
the C. parapsilosis, the hydroalcoholic extracts were the most effective preparations, 
followed by methanolic, aqueous and ethanolic extracts. Punica granatum 
hydroalcoholic extract (MIC = 0.0039 mg/mL) presented the most pronounced 
antifungal potential against C. parapsilosis. Lastly, aqueous extracts were the most 
efficient plant extract preparations against C. tropicalis, followed by methanolic, 
methanol-dichloromethane and hydroalcoholic extracts. Syzygium aromaticum 
(MIC=0.003125 mg/mL) aqueous extract revealing the highest potential. 
It can be concluded that the type of solvent used in the extraction of the phytochemicals 
(including phenolic compounds) has influence in the final composition of the extract 
and, consequently, in the bioactivity. Nevertheless, the Candida species, as also the 
strains used, had also influence in the antifungal results. Several studies have 
highlighted some aspects involved in the mechanisms of action such as interaction with 
the lipid bilayer of the cell membrane, which consequently affect the membrane 
permeability, respiratory chain and cellular energy production (Tintino et al., 2014), as 
well as the inhibition of the H+-ATPase (Kuete et al., 2010). Beyond that, it is possible 
to distinguish the antifungal potential, between fungistatic and/or fungicidal. The 
majority of the studies reported fungistatic effects of plant extracts (Anibal et al., 2013; 
Barros et al., 2013a; Basile et al., 2013; Correa-Royero et al., 2010; Dzoyem et al., 
2014; Kariba et al., 2001; Kim and Lee, 2012; Kurdelas et al., 2010; Lubian et al., 2010; 
Nordin et al., 2013; Pathak, 2012; Thirach et al., 2003; Tomczykowa et al., 2008; 
Tsuzuki et al., 2007), but there are also some reports evidencing fungicidal effects, most 
of them in a dose-dependent manner (Askun et al., 2008; Barros et al., 2013a; Dzoyem 
et al., 2014; Korukluoglu et al., 2008; Lubian et al., 2010; Nordin et al., 2013; Rajeh et 
al., 2010; Siler et al., 2014; Sule et al., 2012; Yazdani et al., 2009). 
It is crucial to characterize the phytochemical composition of the plant extracts with 
antifungal activity, in order to identify the individual compounds responsible for this 
bioactivity, and to elucidate the main molecular targets in Candida species. Some 
studies have been performed in individual phenolic compounds (one of the most 
abundant molecules in polar extracts), as it will be discussed in the next section but, 
unfortunately, the majority of the studies report anti-Candida activity of crude extracts 
without any chemical characterization.  
 
4.2. The use of phenolic compounds against Candida species 
Phenolic acids, flavonoids and tannins are the most studied groups of phenolic 
compounds, comprising molecules with evidenced antifungal properties. These 
molecules have been isolated from different plant sources, as also commercially 
obtained as pure compounds. 
A commercial sample of gallic acid presented higher antifungal potential against C. 
albicans than the same compound isolated from Lythrum salicaria, Paeonia rockii or 
Pelargonium reniforme subsp. reniforme (Table 8). The same behavior was observed 
for commercial quercetin, in comparison to the one obtained from Buddleja salviifolia 
and Halimodendron halodendron (Table 9). On the other hand, commercial sample of 
salicylic acid presented lower antifungal potential than the same compound isolated 
from Halimodendron halodendron (Table 8). It would be expected a similar bioactivity 
for the same compound, independently of its source. Therefore, the observed 
differences are probably related with the purity grade of the tested compounds, as well 
as with the vehicles/solvents used to test antifungal activities.  
Table 8 shows the activity of phenolic acids (hydroxycinnamic acid derivatives, 
hydroxybenzoic acid derivatives and other related compounds) against Candida species. 
In general, hydroxycinnamic acid derivatives presented lower MICs against Candida 
species, than the hydroxybenzoic acid derivatives. The only exception was reported by 
Faria et al. (2011); however, in this case, it is necessary to take into account that the 
results referred to tested concentrations and not MIC values.  
Analyzing the results by each Candida species, in general, commercial compounds, 
mainly albicanyl caffeate (MIC = 4 µg/mL) presented the most pronounced antifungal 
effects against C. albicans. Two phenolic acid related compounds, dihydro-N-
caffeoyltyramine and trans-N-caffeoyltyramine (MICs = 5 µg/mL) obtained from 
Lycium chinense also evidenced a significant potential, followed by gallic acid isolated 
from Paeonia rockii (30 µg/mL) and gentisic, syringic, vanillic and 4-O-β-D-(6-O-
gentisoylglucosyl)vanillic acids from Stenoloma chusanum (50 µg/mL). Regarding 
other Candida species, only Latte & Kolodziej (2000) report the antifungal activity of 
gallic acid from Pelargonium reniforme subsp. reniforme against C. glabrata (MIC =62 
µg/mL) and C. krusei (MIC = 125 µg/mL). To authors’ knowledge there are only 
reports regarding commercial compounds against C. parapsilosis, C. tropicalis and C. 
lusitaniae. 
The antifungal activity of flavonoids against Candida species is presented in Table 9. 
Commercial compounds displayed slight higher antifungal effects than flavonoids 
isolated from plant sources. Among the commercial compounds, silibinin (MIC=4 
µg/mL), a flavolignan, exerted the most pronounced antifungal activity, against C. 
albicans, followed by apigenin (a flavones), genistein (an isoflavone), naringin (a 
flavanone), quercitin (a flavonol) and silymarin (a flavolignan), which presented similar 
potential (MIC=8 µg/mL). Concerning to the flavonoids derived from plant origin, 2’-
O-Methyllabronisoflavone (16-25 µg/mL) and 9-O-methyl-4-hydroxyboeravinone B 
(48 µg/mL), two isoflavones isolated from Mirabilis jalapa, also presented a 
pronounced antifungal potential against C. albicans, followed by the flavonols 
kaempferol, myricetin, quercitin and rutin from Origanum vulgare subsp. gracile and 
Origanum acutidens (except quercetin and rutin). In general, flavonols (mainly 
represented by kaempferol, myricetin and quercetin), followed by flavanones and 
flavolignans, were the most effective antifungal flavonoids against Candida species. 
Once again, C. albicans was the main studied Candida species, being only tested 
commercial flavonoids against C. parapsilosis and compounds isolated from Origanum 
species against C. glabrata.  
Table 10 shows the antifungal activity of hydrolyzable tannins, stilbenes and xanthones 
against Candida species. Comparing the different hydrolyzable tannins isolated from 
Pelargonium reniforme subsp. reniforme, it is possible to conclude that similar 
antifungal effects were achieved; the obtained MIC values were the same for corilagin, 
glucogallin, methyl ester, pelargoniin and phyllantusiin, against C. albicans, C. glabrata 
and C. krusei. Comparing Pelargonium reniforme subsp. reniforme with Punica 
granatum, the hydrolyzable tannin, punicalagin, exerted higher antifungal effect against 
C. albicans (~128 times higher). Regarding stilbenes, resveratrol and 3,4’-
difluorostilbene gave similar MIC values against C. albicans (Sun et al., 2004), while 
for xanthones the commercial compound mangiferin presented a more pronounced 
effect against C. albicans. 8-Carboxy-methyl-1,3,5,6-tetrahydroxyxanthone gave 
significantly different MIC values for each Candida species; C. krusei and C. 
parapsilosis were the most sensible to the mentioned compound (15.7 µg/mL), while C. 
albicans showed higher resistance (62.5 µg/mL). Among tannins, stilbenes and 
xanthones, the latter seem to be the most efficient, exhibiting lower MICs against 
Candida species.  
Overall, commercial compounds seem to be more efficient than phenolic compounds 
isolated from natural matrices probably due to their higher purity grade. Regarding 
phenolic compounds from natural sources, punicalagin (isolated from Punica 
granatum), followed by dihydro-N-caffeoyltyramine and trans-N-caffeoyltyramine 
(isolated from Lycium chinense), were the most efficient against C. albicans. The 
hydrolyzable tannins, carolagin, glucogallin, methyl ester, pelargonin and phyllantusiin 
(isolated from Pelargonium reniforme subsp. reniforme) were the most efficient for C. 
glabrata, while 8-carboxy-methyl-1,3,5,6-tetrahydroxyxanthone, a xanthone isolated 
from Leiothrix spiralis, was the most effective against C. krusei and C. tropicalis. 
Lastly, for C. parapsilosis, punicalagin (isolated from Punica granatum), followed by 
8-carboxy-methyl-1,3,5,6-tetrahydroxyxanthone (isolated from Leiothrix spiralis), 
presented the most pronounced effects. 
 
5. Conclusions 
Being part of the commensal flora, Candida species are also related to several situations 
of overgrowth, and an increasing resistance to the current antifungal drugs has been 
observed. Despite the efforts in order to discover and/or synthetize new chemical 
molecules, more efficient and effective than the existents, it is necessary to consider that 
these compounds could be associated to a wide variety of side effects. Beyond that, 
those experiments are very expensive and take a long time until the 
accreditation/commercialization of the products. Medicinal plants are used since ancient 
times and present several bioactive properties, due to their richness in some 
biomolecules, such as phenolic compounds. Several studies have been developed 
towards investigating the antifungal properties of phenolic compounds enriched 
extracts, against Candida species. For that, different extraction solvents have been used, 
namely, water, ethanol, methanol, methanol-dichloromethane and even mixtures of the 
previous. In parallel, and due to the high antifungal potential evidenced by some plant 
extracts, an increasing number of studies have been evaluating the antifungal potential 
of phenolic compounds isolated from those matrices. 
Despite the existence of a tenuous variation on the antifungal activity according to 
Candida species, in general, the plant extracts obtained using methanol, water and 
mixtures of the previous (hydroalcoholic extracts) were more effective against Candida 
species than the extracts prepared using a unique solvent. This higher antifungal activity 
might be related with the solubility of the active principles in the solvents used; 
phenolic compounds are one of the most abundant bioactive molecules present in those 
polar extracts. Hydrolysable tannins, followed by some phenolic amides and flavonoids 
seem to exert the most pronounced anti-Candida effects. There are some evidences that 
the mentioned extracts/compounds affect fungal cells through interaction with the lipid 
bilayer of the cell membrane. They could act by disrupting the membrane integrity or by 
intercalation into cell wall and/or DNA. Nevertheless, much more studies are necessary 
not only to evaluate the antifungal potential of the reviewed and other medicinal plants, 
but also to establish clearly mechanisms of action involved in potential of phenolic 




The authors are grateful to Foundation for Science and Technology (FCT, Portugal) for 
N. Martins grant (SFRH/BD/87658/2012), L. Barros researcher contract under 
“Programa Compromisso com Ciência – 2008” and financial support to the research 
centre CIMO (strategic project PEst-OE/AGR/UI0690/2011). This work was also 
supported by the Programa Operacional, Fatores de competitividade – COMPETE and 
by national funds through FCT – Fundação para a Ciência e a Tecnologia on the scope 
of the projects FCT PTDC/SAU-MIC/119069/2010, RECI/EBB-EBI/0179/2012 and 
PEst-OE/EQB/LA0023/2013. The authors thank the Project “BioHealth - 
Biotechnology and Bioengineering approaches to improve health quality", Ref. 
NORTE-07-0124-FEDER-000027, co-funded by the Programa Operacional Regional 
do Norte (ON.2 – O Novo Norte), QREN, FEDER. 
 
References 
Abdul, B.A., Hassan, A.M., Hassan, A.S., 2012. In vitro antimicrobial activity of 
Thymus vulgaris, Origanum vulgare and Rosmarinus officinalis against dental 
caries pathogens. Haitham J. Pure Appl. Sci. 25, 1–7. 
Abi-Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H., Vartivarian, S., 1997. 
The epidemiology of hematogenous candidiasis caused by different Candida 
species. Clin. Infect. Dis. 24, 1122–1128. 
Adekunle, A.A., Ikumapayi, A.M., 2006. Antifungal property and phytochemical 
screening of the crude extracts of Funtumia elastica and Mallotus oppositifolius. 
West Indian Med. J. 55, 9–13. 
Agarwal, V., Lal, P., Pruthi, V., 2010. Effect of plant oils on Candida albicans. J. 
Microbiol. Immunol. Infect. 43, 447–451.  
Ali-Shtayeh, M.S., Ghdeib, S.I.A., 1999. Antifungal activity of plant extracts against 
dermatophytes. Mycoses 42, 665–672. 
Alves, M.J., Ferreira, I.C.F.R., Dias, J., Teixeira, V., Martins, A., Pintado, M., 2013. A 
review on antifungal activity of mushroom (basidiomycetes) extracts and isolated 
compounds. Curr. Top. Med. Chem. 13, 2648–2659. 
Alves-Silva, J.M., Santos, S.M.D., Pintado, M.E., Pérez-Álvarez, J.A., Fernández-
López, J., Viuda-Martos, M., 2013. Chemical composition and in vitro 
antimicrobial, antifungal and antioxidant properties of essential oils obtained from 
some herbs widely used in Portugal. Food Control 32, 371–378.  
Amara, A.A., Shibl, A., 2013. Role of probiotics in health improvement, infection 
control and disease treatment and management. Saudi Pharm. J. 1–8.  
Anibal, P.C., Peixoto, I.T.A., Foglio, M.A., Höfling, J.F., 2013. Antifungal activity of 
the ethanolic extracts of Punica granatum L. and evaluation of the morphological 
and structural modifications of its compounds upon the cells of Candida spp. 
Brazilian J. Microbiol. 44, 839–848.  
Araújo, M.G.F., Hilário, F., Vilegas, W., Santos, L.C., Brunetti, I.L., Sotomayor, C.E., 
Bauab, T.M., 2012. Correlation among antioxidant, antimicrobial, hemolytic, and 
antiproliferative properties of Leiothrix spiralis leaves extract. Int. J. Mol. Sci. 13, 
9260–9277.  
Araújo, M.G.D.F., Hilário, F., Nogueira, L.G., Vilegas, W., Santos, L.C., Bauab, T.M., 
2011. Chemical constituents of the methanolic extract of leaves of Leiothrix 
spiralis Ruhland and their antimicrobial activity. Molecules 16, 10479–10490.  
Arif, T., Bhosale, J.D., Kumar, N., Mandal, T.K., Bendre, R.S., Lavekar, G.S., Dabur, 
R., 2009. Natural products - antifungal agents derived from plants. J. Asian Nat. 
Prod. Res. 11, 621–638. 
Arif, T., Mandal, T.K., Dabur, R., 2011. Natural products: Anti-fungal agents derived 
from plants, in: Opportunity, challenge and ccope of natural products in Medicinal 
Chemistry. pp. 283–311. 
Asgarpanah, J., Kazemivash, N., 2012. Phytochemistry, pharmacology and medicinal 
properties of Coriandrum sativum L. African J. Pharm. Pharmacol. 6, 2340–2345.  
Ashour, H.M., 2008. Antibacterial, antifungal, and anticancer activities of volatile oils 
and extracts from stems, leaves, and flowers of Eucalyptus sideroxylon and 
Eucalyptus torquata. Cancer Biol. Ther. 7, 399–403. 
Askun, T., Tumen, G., Satil, F., Kilic, T., 2008. Effects of some Lamiaceae species 
methanol extracts on potential mycotoxin producer fungi. Pharm. Biol. 46, 688–
694. 
Asl, M.N., Hosseinzadeh, H., 2008. Review of pharmacological effects of Glycyrrhiza 
sp . and its bioactive compounds. Phyther. Res. 22, 709–724.  
Asmundsdóttir, L.R., Erlendsdóttir, H., Agnarsson, B.A., Gottfredsson, M., 2009. The 
importance of strain variation in virulence of Candida dubliniensis and Candida 
albicans: results of a blinded histopathological study of invasive candidiasis. Clin. 
Microbiol. Infect. 15, 576–585.  
Bakkali, F., Averbeck, S., Averbeck, D., Idaomar, M., 2008. Biological effects of 
essential oils - A review. Food Chem. Toxicol. 46, 446–475.  
Balch, P.A., 2006. Prescription for Nutritional Healing, Fourth Edi. ed. Penguin Group, 
London, England. 
Barros, L., Alves, C.T., Dueñas, M., Silva, S., Oliveira, R., Carvalho, A.M., Henriques, 
M., Santos-Buelga, C., Ferreira, I.C.F.R., 2013a. Characterization of phenolic 
compounds in wild medicinal flowers from Portugal by HPLC–DAD–ESI/MS and 
evaluation of antifungal properties. Ind. Crops Prod. 44, 104–110.  
Barros, L., Dueñas, M., Alves, C.T., Silva, S., Henriques, M., Santos-Buelga, C., 
Ferreira, I.C.F.R., 2013b. Antifungal activity and detailed chemical 
characterization of Cistus ladanifer phenolic extracts. Ind. Crops Prod. 41, 41–45. 
Basile, A., Rigano, D., Conte, B., Bruno, M., Rosselli, S., Sorbo, S., 2013. Antibacterial 
and antifungal activities of acetonic extract from Paullinia cupana Mart. seeds. 
Nat. Prod. Res. 27, 2084–2090.  
Bhalodia, N.R., Nariya, P.B., Acharya, R.N., Shukla, V.J., 2012. In vitro antibacterial 
and antifungal activities of Cassia fistula Linn. fruit pulp extracts. Ayu 33, 123–
129.  
Blanco, J.L., Garcia, M.E., 2008. Immune response to fungal infections. Vet. Immunol. 
Immunopathol. 125, 47–70.  
Brunke, S., Hube, B., 2013. Two unlike cousins: Candida albicans and C. glabrata 
infection strategies. Cell. Microbiol. 15, 701–708.  
Camacho-Hernández, I.L., Cisneros-Rodríguez, C., Uribe-Beltrán, M.J., Ríos-Morgan, 
A., Delgado-Vargas, F., 2004. Antifungal activity of fruit pulp extract from 
Psidium sartorianum. Fitoterapia 75, 401–404.  
Campos, L., 2008. Entender a bioquimica, 5th Edition. ed. 
Cardoso, A.M.R., Cavalcanti, Y.W., Almeida, L.F.D., Pérez, A.L.A.L., Padilha, 
W.W.N., 2012. Antifungal activity of plant-based tinctures on Candida. RSBO 9, 
25–30. 
Carocho, M., Ferreira, I.C.F.R., 2013a. A review on antioxidants, prooxidants and 
related controversy: natural and synthetic compounds, screening and analysis 
methodologies and future perspectives. Food Chem. Toxicol. 51, 15–25.  
Carocho, M., Ferreira, I.C.F.R., 2013b. The role of phenolic compounds in the fight 
against cancer - a review. Anticancer. Agents Med. Chem. 13, 1236–1258. 
Carrara, M.A., Donatti, L., Damke, E., Svidizinski, T.I.E., Consolaro, M.E.L., Batista, 
M.R., 2010. A new model of vaginal infection by Candida albicans in rats. 
Mycopathologia 170, 331–338.  
Çekiç, S.D., Cetinkaya, A., Avan, A.N., Apak, R., 2013. Correlation of total antioxidant 
capacity with reactive oxygen species (ROS) consumption measured by oxidative 
conversion. J. Agric. Food Chem. 61, 5260–5270.  
Chaturvedi, R.K., Beal, M.F., 2013. Mitochondrial diseases of the brain. Free Radic. 
Biol. Med. 63, 1–29.  
Choudhary, M.I., Atta-ur-Rahmant, 1999. Recent studies on bioactive natural products. 
Pure Appl. Chem. 71, 1079–1081. 
Coopoosamy, R.M., Magwa, M.L., 2007. Traditional use, antibacterial activity and 
antifungal activity of crude extract of Aloe excelsa. African J. Biotechnol. 6, 2406–
2410. 
Correa-Royero, J., Tangarife, V., Durán, C., Stashenko, E., Mesa-Arango, A., 2010. In 
vitro antifungal activity and cytotoxic effect of essential oils and extracts of 
medicinal and aromatic plants against Candida krusei and Aspergillus fumigatus. 
Brazilian J. Pharmacogn. 20, 734–741. 
Dai, J., Mumper, R.J., 2010. Plant phenolics: extraction, analysis and their antioxidant 
and anticancer properties. Molecules 15, 7313–7352.  
Darwish, R.M., Aburjai, T.A., 2011. Antimicrobial activity of some medicinal plants 
against different Candida species. Jordan J. Pharm. Sci. 4, 70–80. 
Devasagayam, T.P.A., Tilak, J.C., Boloor, K.K., Sane, K.S., Ghaskadbi, S.S., Lele, 
R.D., 2004. Free radicals and antioxidants in human health: current status and 
future prospects. J. Assoc. Physicians India 52, 794–804. 
Develoux, M., Bretagne, S., 2005. Candidoses et levuroses diverses. EMC - Mal. Infect. 
2, 119–139.  
Dib, M.A., Djabou, N., Allali, H., Tabti, B., 2010. Identification of phenolic compounds 
and antimicrobial activity of roots of Arbutus unedo L. Asian J. Chem. 22, 4045–
4053. 
Doddanna, S.J., Patel, S., Sundarrao, M.A., Veerabhadrappa, R.S., 2013. Antimicrobial 
activity of plant extracts on Candida albicans: an in vitro study. Indian J. Dent. 
Res. 24, 401–405. 
Džamić, A.M., Soković, M.D., Novaković, M., Jadranin, M., Ristić, M.S., Tešević, V., 
Marin, P.D., 2013. Composition, antifungal and antioxidant properties of Hyssopus 
officinalis L. subsp. pilifer (Pant.) Murb. essential oil and deodorized extracts. Ind. 
Crops Prod. 51, 401–407. 
Dzoyem, J.P., Kechia, F.A., Kuete, V., Pieme, A.C., Akak, C.M., Tangmouo, J.G., 
Lohoue, P.J., 2011. Phytotoxic, antifungal activities and acute toxicity studies of 
the crude extract and compounds from Diospyros canaliculata. Nat. Prod. Res. 25, 
741–749. 
Dzoyem, J.P., Tangmouo, J.G., Lontsi, D., Etoa, F.X., Lohoue, P.J., 2007. In vitro 
antifungal activity of extract and plumbagin from the stem bark of Diospyros 
crassiflora Hiern (Ebenaceae). Phyther. Res. 21, 671–674.  
Dzoyem, J.P., Tchuenguem, R.T., Kuiate, J.R., Teke, G.N., Kechia, F.A., Kuete, V., 
2014. In vitro and in vivo antifungal activities of selected Cameroonian dietary 
spices. BMC Complement. Altern. Med. 14, 1–8.  
Eggimann, P., Garbino, J., Pittet, D., 2003a. Epidemiology of Candida species 
infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3, 
685–702. 
Eggimann, P., Garbino, J., Pittet, D., 2003b. Management of Candida species infections 
in critically ill patients. Lancet Infect. Dis. 3, 772–785. 
Endo, E.H., Cortez, D.A.G., Ueda-Nakamura, T., Nakamura, C.V., Filho, B.P.D., 2010. 
Potent antifungal activity of extracts and pure compound isolated from 
pomegranate peels and synergism with fluconazole against Candida albicans. Res. 
Microbiol. 161, 534–540.  
Epstein, J.B., Polsky, B., 1998. Oropharyngeal candidiasis: a review of its clinical 
spectrum and current therapies. Clin. Ther. 20, 40–57. 
Ertürk, Ö., 2006. Antibacterial and antifungal activity of ethanolic extracts from eleven 
spice plants. Biologia (Bratisl). 61, 275–278. 
Ettefagh, K.A, Burns, J.T., Junio, H.A, Kaatz, G.W., Cech, N.B., 2011. Goldenseal 
(Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity 
of berberine via efflux pump inhibition. Planta Med. 77, 835–840. 
Fanello, S., Bouchara, J.P., Jousset, N., Delbos, V., LeFlohic, A.M., 2001. Nosocomial 
Candida albicans acquisition in a geriatric unit: epidemiology and evidence for 
person-to-person transmission. J. Hosp. Infect. 47, 46–52.  
Farhat, M. Ben, Jordán, M.J., Chaouech-Hamada, R., Landoulsi, A., Sotomayor, J.A., 
2009. Variations in essential oil, phenolic compounds, and antioxidant activity of 
tunisian cultivated Salvia officinalis L. J. Agric. Food Chem. 57, 10349–10356.  
Farhat, M. Ben, Landoulsi, A., Chaouch-Hamada, R., Sotomayor, J.A., Jordán, M.J., 
2013. Characterization and quantification of phenolic compounds and antioxidant 
properties of Salvia species growing in different habitats. Ind. Crops Prod. 49, 
904–914.  
Faria, N.C.G., Kim, J.H., Gonçalves, L.A.P., Martins, M. de L., Chan, K.L., Campbell, 
B.C., 2011. Enhanced activity of antifungal drugs using natural phenolics against 
yeast strains of Candida and Cryptococcus. Lett. Appl. Microbiol. 52, 506–513.  
Fatima, A., Gupta, V.K., Luqman, S., Negi, A.S., Kumar, J.K., Shanker, K., Saikia, D., 
Srivastava, S., Darokar, M.P., Khanuja, S.P.S., 2009. Antifungal activity of 
Glycyrrhiza glabra extracts and its active constituent glabridin. Phyther. Res. 
1193, 1190–1193. 
Fei, L.C., Chen, P.Y., Ahmad, Z., Othman, F., Pei Pei, C., 2008. Antifungal properties 
of Allium sativum extracts on Candida species. J. Trop. Med. Plants 9, 43–48. 
Franz, R., Kelly, S.L., Lamb, D.C., Kelly, D.E., Ruhnke, M., Morschhäuser, J., 1998. 
Multiple molecular mechanisms contribute to a stepwise development of 
fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents 
Chemother. 42, 3065–3072. 
Geiger, A.M., Foxman, B., Sobel, J.D., 1995. Chronic vulvovaginal candidiasis: 
characteristics of women with Candida albicans, C. glabrata and no Candida. 
Genitourin. Med. 71, 304–307. 
Ghannoum, M.A., Rice, L.B., 1999. Antifungal agents: mode of action, mechanisms of 
resistance, and correlation of these mechanisms with bacterial resistance. Clin. 
Microbiol. Rev. 12, 501–517. 
Ghasemi Pirbalouti, A., Hashemi, M., Ghahfarokhi, F.T., 2013. Essential oil and 
chemical compositions of wild and cultivated Thymus daenensis Celak and Thymus 
vulgaris L. Ind. Crops Prod. 48, 43–48.  
Giada, M.D.L.R., 2013. Food phenolic compounds: main classes, sources and their 
antioxidant power, in: Morales-González, J.A. (Ed.), Oxidative Stress and Chronic 
Degenerative Diseases - A Role for Antioxidants. InTech, Chapters, Rio de Janeiro 
- RJ, p. 501. 
Greenberg, M.S., Glick, M., 2003. Burket’s Oral Medicine: Diagnosis and Treatment, 
10 Edition. ed. BC Decker Inc., USA. 
Gubbins, P.O., Anaissie, E.J., 2009. Antifungal therapy, in: Livingstone, C. (Ed.), 
Clinical Mycology. Elsevier, pp. 165–199. 
Halberstein, R.A., 2005. Medicinal plants: historical and cross-cultural usage patterns. 
Ann. Epidemiol. 15, 686–699.  
Hashem, M., 2011. Antifungal properties of crude extracts of five Egyptian medicinal 
plants against dermatophytes and emerging fungi. Mycopathologia 172, 37–46.  
Hassawi, D., Kharma, A., 2006. Antimicrobial activity of some medicinal plants against 
Candida albicans. J. Biol. Sci. 6, 109–114.  
Höfling, J.F., Mardegan, R.C., Anibal, P.C., Furletti, V.F., Foglio, M.A., 2011. 
Evaluation of antifungal activity of medicinal plant extracts against oral Candida 
albicans and proteinases. Mycopathologia 172, 117–124. 
Inbaraj, J.J., Kukielczak, B.M., Bilski, P., He, Y.-Y., Sik, R.H., Chignell, C.F., 2006. 
Photochemistry and photocytotoxicity of alkaloids from goldenseal (Hydrastis 
canadensis L.) 2. Palmatine, hydrastine, canadine, and hydrastinine. Chem. Res. 
Toxicol. 19, 739–744. 
Inbaraj, J.J., Kukielczak, B.M., Bilski, P., Sandvik, S.L., Chignell, C.F., 2001. 
Photochemistry and photocytotoxicity of alkaloids from goldenseal (Hydrastis 
canadensis L.) 1. Berberine. Chem. Res. Toxicol. 14, 1529–1534. 
Irshad, Shreaz, S., Manzoor, N., Khan, L.A., Rizvi, M.M.A., 2011. Anticandidal 
activity of Cassia fistula and its effect on ergosterol biosynthesis. Pharm. Biol. 49, 
727–733.  
Ishaq, M.S., Hussain, M.M., Afridi, M.S., Ali, G., Khattak, M., Ahmad, S., Shakirullah, 
2014. In vitro phytochemical, antibacterial, and antifungal activities of leaf, stem, 
and root extracts of Adiantum capillus veneris. Sci. world J. 2014, 1–7. 
Isolauri, E., Kirjavainen, P. V., Salminen, S., 2002. Probiotics: a role in the treatment of 
intestinal infection and inflammation? Gut 50, 54–59. 
Jainkittivong, A., Butsarakamruha, T., Langlais, R.P., 2009. Antifungal activity of 
Morinda citrifolia fruit extract against Candida albicans. Oral Surg. Oral Med. 
Oral Pathol. Oral Radiol. Endod. 108, 394–398.  
Jasim, R.M., Al-khaliq, I.M.A., 2011. Inhibitory effect of aqueous Salvia officinalis’s 
leaves in the growth of Candida albicans from infected women with vaginal 
candidiasis. Al-Kindy Coll. Med. J. 6, 47–49. 
Joe, M.M., Jayachitra, J., Vijayapriya, M., 2009. Antimicrobial activity of some 
common spices against certain human pathogens. J. Med. Plants Res. 3, 1134–
1136. 
Jung, H.J., Hwang, I.A., Sung, W.S., Kang, H., Kang, B.S., Seu, Y.B., Lee, D.G., 2005. 
Fungicidal effect of resveratrol on human infectious fungi. Arch. Pharm. Res. 28, 
557–560. 
Junio, H.A., Sy-Cordero, A.A., Ettefagh, K.A., Burns, J.T., Micko, K.T., Graf, T.N., 
Richter, S.J., Cannon, R.E., Oberlies, N.H., Cech, N.B., 2011. Synergy-directed 
fractionation of botanical medicines: A case study with goldenseal (Hydrastis 
canadensis). J. Nat. Prod. 74, 1621–1629.  
Kaewpiboon, C., Lirdprapamongkol, K., Srisomsap, C., Winayanuwattikun, P., 
Yongvanich, T., Puwaprisirisan, P., Svasti, J., Assavalapsakul, W., 2012. Studies 
of the in vitro cytotoxic, antioxidant, lipase inhibitory and antimicrobial activities 
of selected Thai medicinal plants. BMC Complement. Altern. Med. 12, 1-8.  
Kanafani, Z.A., Perfect, J.R., 2008. Resistance to antifungal agents: mechanisms and 
clinical impact. Clin. Infect. Dis. - Antimicrob. Resist. 46, 120–128.  
Kariba, R.M., Siboe, G.M., Dossaji, S.F., 2001. In vitro antifungal activity of 
Schizozygia coffaeoides bail. (Apocynaceae) extracts. J. Ethnopharmacol. 74, 41–
44. 
Karomi, M.F., Huda, S.A., Kadhim, S.I., Salman, Z.O., 2012. Effect of methanolic 
extracts of different parts of Liquorice Glycyrrhiza glabra L . on growth of some 
pathogenic bacteria and fungus Candida albicans. Iraq Acad. Sci. Journals 4, 140–
150. 
Kaur, I.P., Kuhad, A., Garg, A., Chopra, K., 2009. Probiotics: delineation of 
prophylactic and therapeutic benefits. J. Med. Food 12, 219–235.  
Kim, J., Sudbery, P., 2011. Candida albicans, a major human fungal pathogen. J. 
Microbiol. 49, 171–177.  
Kim, Y., Lee, H., 2012. Anticandidal effect of Syzygium aromaticum on biofilm 
formation, cell surface hydrophobicity, and cell cycle. J. Med. Plants Res. 6, 1926–
1934. 
Kontoyiannis, D.P., Lewis, R.E., 2002. Antifungal drug resistance of pathogenic fungi. 
Lancet 359, 1135–1144.  
Korukluoglu, M., Gurbuz, O., Sahan, Y., Yigit, A., Kacar, O., Rouseff, R., 2008. 
Chemical characterization and antifungal activity of Origanum onites L. essential 
oils and extracts. J. Food Saf. 29, 144–161. 
Kosalec, I., Pepeljnjak, S., Kustrak, D., 2005. Antifungal activity of fluid extract and 
essential oil from anise fruits (Pimpinella anisum L., Apiaceae). Acta Pharm. 55, 
377–385. 
Kostić, D.A., Velicković, J.M., Mitić, S.S., Mitić, M.N., Randelović, S.S., 2012. 
Phenolic content, and antioxidant and antimicrobial activities of Crataegus 
oxyacantha L (Rosaceae ) fruit extract from southeast serbia. Trop. J. Pharm. Res. 
11, 117–124. 
Krisch, J., Ördögh, L., Galgóczy, L., Papp, T., Vágvölgyi, C., 2008. Anticandidal effect 
of berry juices and extracts from Ribes species. Cent. Eur. J. Biol. 4, 86–89.  
Ksouri, R., Ksouri, W.M., Jallali, I., Debez, A., Magné, C., Hiroko, I., Abdelly, C., 
2012. Medicinal halophytes: potent source of health promoting biomolecules with 
medical, nutraceutical and food applications. Crit. Rev. Biotechnol. 32, 289–326. 
Kuete, V., Poumale, H.M.P., Guedem, A.N., Shiono, Y., Randrianasolo, R., Ngadjui, 
B.T., 2010. Antimycobacterial, antibacterial and antifungal activities of the 
methanol extract and compounds from Thecacoris annobonae (Euphorbiaceae). 
South African J. Bot. 76, 536–542.  
Kurdelas, R.R., Lima, B., Tapia, A., Feresin, G.E., Gonzalez Sierra, M., Rodríguez, 
M.V., Zacchino, S., Enriz, R.D., Freile, M.L., 2010. Antifungal activity of extracts 
and prenylated coumarins isolated from Baccharis darwinii Hook & Arn. 
(Asteraceae). Molecules 15, 4898–4907.  
Kursat, M., Emre, I., Yılmaz, Ö., Erecevit, P., 2011. Antioxidant and antimicrobial 
activity in the seeds of Origanum vulgare L . subs. gracile (C . Koch) Ietswaart 
and Origanum acutidens (Hand.-Mazz.) Ietswaart from Turkey. Grasas y aceites 
62, 410–417. 
Kwamin, F., Nartey, N.O., Codjoe, F.S., Newman, M.J., 2013. Distribution of Candida 
species among HIV-positive patients with oropharyngeal candidiasis in Accra , 
Ghana. J. Infect. Dev. Ctries. 7, 041–045. 
Lamb, D., Kelly, D., Kelly, S., 1999. Molecular aspects of azole antifungal action and 
resistance. Drug Resist. Updat. 2, 390–402.  
Latte, K.P., Kolodziej, H., 2000. Antifungal effects of hydrolysable tannins and related 
compounds on dermatophytes, mould fungi and yeasts. Zeitschrift fur Naturforsch. 
C - A J. Biosci. 55, 467–472. 
Lee, D.G., Park, Y., Kim, M.-R., Jung, H.J., Seu, Y.B., Hahm, K.-S., Woo, E.-R., 2004. 
Anti-fungal effects of phenolic amides isolated from the root bark of Lycium 
chinense. Biotechnol. Lett. 26, 1125–1130.  
Lewis, L.E., Bain, J.M., Lowes, C., Gow, N.A.R., Erwig, L.-P., 2012. Candida albicans 
infection inhibits macrophage cell division and proliferation. Fungal Genet. Biol. 
49, 679–680. 
Li, S.Y., Yang, Y.L., Chen, K.W., Cheng, H.H., Chiou, C.S., Wang, T.H., Lauderdale, 
T.L., Hung, C.C., Lo, H.J., 2006. Molecular epidemiology of long-term 
colonization of Candida albicans strains from HIV-infected patients. Epidemiol. 
Infect. 134, 265–269.  
Ličina, B.Z., Stefanović, O.D., Vasić, S.M., Radojević, I.D., Dekić, M.S., Čomić, L.R., 
2013. Biological activities of the extracts from wild growing Origanum vulgare L. 
Food Control 33, 498–504.  
Lim, S.H., Darah, I., Jain, K., 2006. Antimicrobial activities of tannins extracted from 
Rhizophora apiculata barks. J. Trop. For. Sci. 18, 59–66. 
Liu, X.P., Fan, S.R., Bai, F.Y., Li, J., Liao, Q.P., 2009. Antifungal susceptibility and 
genotypes of Candida albicans strains from patients with vulvovaginal candidiasis. 
Mycoses 52, 24–28.  
Lott, T.J., Fundyga, R.E., Kuykendall, R.J., Arnold, J., 2005. The human commensal 
yeast, Candida albicans, has an ancient origin. Fungal Genet. Biol. 42, 444–451.  
Lu, Q., Jayatilake, J.A.M.S., Samaranayake, L.P., Jin, L., 2006. Hyphal invasion of 
Candida albicans inhibits the expression of human beta-defensins in experimental 
oral candidiasis. J. Invest. Dermatol. 126, 2049–2056.  
Lubian, C.T., Teixeira, J.M., Lund, R.G., Nascente, P.S., Del Pino, F.A.B., 2010. 
Antifungal activity of the aqueous extract from Arctium minus (Hill) Bernh. 
(Asteraceae) on oral Candida species. Brazilian J. Med. Plants 12, 157–162. 
Lupetti, A., Danesi, R., Campa, M., Del Tacca, M., Kelly, S., 2002. Molecular basis of 
resistance to azole antifungals. Trends Mol. Med. 8, 76–81. 
Lupetti, A., Nibbering, P.H., Campa, M., Del Tacca, M., Danesi, R., 2003. Molecular 
targeted treatments for fungal infections: the role of drug combinations. Trends 
Mol. Med. 9, 269–276.  
Madhumitha, G., Saral, A.M., 2011. Preliminary phytochemical analysis, antibacterial, 
antifungal and anticandidal activities of successive extracts of Crossandra 
infundibuliformis. Asian Pac. J. Trop. Med. 4, 192–195. 
Manayi, A., Saeidnia, S., Faramarzi, M.A., Samadi, N., Jafari, S., Vazirian, M., 
Ghaderi, A., Mirnezami, T., Hadjiakhoondi, A., Ardekani, M.R.S., Khanavi, M., 
2013. A comparative study of anti-Candida activity and phenolic contents of the 
calluses from Lythrum salicaria L. in different treatments. Appl. Biochem. 
Biotechnol. 170, 176–184.  
Mandeel, Q., Taha, A., 2005. Assessment of in vitro antifungal activities of various 
extracts of indigenous bahraini medicinal plants. Pharm. Biol. 43, 340–348.  
Martins, N., Barros, L., Santos-Buelga, C., Henriques, M., Silva, S., Ferreira, I.C.F.R., 
2015. Evaluation of bioactive properties and phenolic compounds in different 
extracts prepared from Salvia officinalis L. Food Chem. 170, 378–385.  
Martins, N., Ferreira, I.C.F.R., Barros, L., Silva, S., Henriques, M., 2014. Candidiasis: 
predisposing factors, prevention, diagnosis and alternative treatment. 
Mycopathologia 177, 223–240. 
Masoko, P., Mmushi, T.J., Mogashoa, M.M., Mokgotho, M.P., Mampuru, L.J., Howard, 
R.L., 2008. In vitro evaluation of the antifungal activity of Sclerocarya birrea 
extracts against pathogenic yeasts. African J. Biotechnol. 7, 3521–3526. 
Masoko, P., Picard, J., Howard, R.L., Mampuru, L.J., Eloff, J.N., 2010. In vivo 
antifungal effect of Combretum and Terminalia species extracts on cutaneous 
wound healing in immunosuppressed rats. Pharm. Biol. 48, 621–632.  
Mathur, A., Singh, R., Yousuf, S., Bhardwaj, A., Verma, S.K., Babu, P., Gupta, V., 
Prasad, G.B.K.S., Dua, V.K., 2011. Antifungal activity of some plant extracts 
against clinical pathogens. Adv. Appl. Sci. Res. 2, 260–264. 
Maurya, I.K., Thota, C.K., Sharma, J., Tupe, S.G., Chaudhary, P., Singh, M.K., Thakur, 
I.S., Deshpande, M., Prasad, R., Chauhan, V.S., 2013. Mechanism of action of 
novel synthetic dodecapeptides against Candida albicans. Biochim. Biophys. Acta 
1830, 5193–5203.  
Mayer, F.L., Wilson, D., Hube, B., 2013. Candida albicans pathogenicity mechanisms. 
Virulence 4, 119–128.  
McCullough, M.J., Ross, B.C., Reade, P.C., 1996. Candida albicans: a review of its 
history, taxonomy, epidemiology, virulence attributes, and methods of strain 
differentiation. Int. J. Oral Maxillofac. Surg. 25, 136–144. 
Menezes, T.O.A., Alves, A.C.B.A., Vieira, J.M.S., Menezes, S.A.F., Alves, B.P., 
Mendonça, L.C.V., 2009. In vitro evaluation of the antifungal activity of essential 
oils and plant extracts from Amazonian region against Candida albicans. J. 
Odontol. UNESP 38, 184–191. 
Modaressi, M., Shahsavari, R., Ahmadi, F., Rahimi-Nasrabadi, M., Abiri, R., Mikaeli, 
A., Batoli, H., 2013. The evaluation of antibacterial, antifungal and antioxidant 
activity of methanolic extract of Mindium laevigatum (Vent.) Rech. F., from 
central part of Iran. Jundishapur J. Nat. Pharm. Prod. 8, 34–40. 
Murray, M.T., 2004. The healing power of herbs, 2nd ed. Random House, New York, 
NY. 
Murray, M.T., Pizzorno, J., 1998. Enciclopedia de Medicina Natural, 2a Edicion. ed. 
Ediciones Tutor S.A., Espanha. 
Nelson, D.L., Cox, M.M., 2000. Lehninger Principles of Biochemistry, Third Edit. ed. 
Worth Publishers, Inc, New York. 
Ngameni, B., Kuete, V., Simo, I.K., Mbaveng, A.T., Awoussong, P.K., Patnam, R., 
Roy, R., Ngadjui, B.T., 2009. Antibacterial and antifungal activities of the crude 
extract and compounds from Dorstenia turbinata (Moraceae). South African J. 
Bot. 75, 256–261. 
Niño, J., Narváez, D.M., Mosquera, O.M., Correa, Y.M., 2007. Antibacterial, antifungal 
and cytotoxic activities of eight Asteraceae and two Rubiaceae plants from 
Colombian biodiversity. Brazilian J. Microbiol. 566–570. 
Noël, T., 2012. The cellular and molecular defense mechanisms of the Candida yeasts 
against azole antifungal drugs. J. Mycol. Med. 22, 173–178.  
Nordin, M.-A.-F., Harun, W.H.A.W., Razak, F.A., 2013. Antifungal susceptibility and 
growth inhibitory response of oral Candida species to Brucea javanica Linn. 
extract. BMC Complement. Altern. Med. 13, 1–8.  
Ozçelik, B., Kartal, M., Orhan, I., 2011. Cytotoxicity, antiviral and antimicrobial 
activities of alkaloids, flavonoids, and phenolic acids. Pharm. Biol. 49, 396–402.  
Papageorgiou, V., Gardeli, C., Mallouchos, A., Papaioannou, M., Komaitis, M., 2008. 
Variation of the chemical profile and antioxidant behavior of Rosmarinus 
officinalis L. and Salvia fruticosa Miller grown in Greece. J. Agric. Food Chem. 
56, 7254–7264. 
Parekh, J., Chanda, S., 2008. In vitro antifungal activity of methanol extracts of some 
Indian medicinal plants against pathogenic yeast and moulds. African J. 
Biotechnol. 7, 4349–4353. 
Parsaeimehr, A., Sargsyan, E., Javidnia, K., 2010. A comparative study of the 
antibacterial, antifungal and antioxidant activity and total content of phenolic 
compounds of cell cultures and wild plants of three endemic species of Ephedra. 
Molecules 15, 1668–1678. 
Pathak, A.K., 2012. Anti-Candida activity of aqueous extracts of some herbals. Indian 
J. Fundam. Appl. Life Sci. 2, 1–6. 
Pendota, S.C., Aderogba, M.A., Ndhlala, A.R., Staden, J.V, 2013. Antimicrobial and 
acetylcholinesterase inhibitory activities of Buddleja salviifolia (L.) Lam. leaf 
extracts and isolated compounds. J. Ethnopharmacol. 148, 515–520.  
Pereira Gonzales, F., Maisch, T., 2012. Photodynamic inactivation for controlling 
Candida albicans infections. Fungal Biol. 116, 1–10.  
Perlin, D.S., 2009. Resistance to echinocandin-class antifungal drugs. Drug Resist. 
Updat. 10, 121–130. 
Perlin, D.S., 2014. Current perspectives on echinocandin class drugs. Future Microbiol. 
6, 441–457. 
Pessini, G.L., Filho, B.P.D., Nakamura, C.V., Cortez, D.A.G., 2005. Antifungal activity 
of the extracts and neolignans from Piper regnellii (Miq.) C. DC. var. pallescens 
(C. DC.) Yunck. J. Braz. Chem. Soc. 16, 1130–1133. 
Petrovska, B.B., 2012. Historical review of medicinal plants’ usage. Pharmacogn. Rev. 
6, 1–5. 
Picerno, P., Mencherini, T., Sansone, F., Gaudio, P. Del, Granata, I., Porta, A., Aquino, 
R.P., 2011. Screening of a polar extract of Paeonia rockii: composition and 
antioxidant and antifungal activities. J. Ethnopharmacol. 138, 705–712.  
Pierce, G.E., 2005. Pseudomonas aeruginosa, Candida albicans, and device-related 
nosocomial infections: implications, trends, and potential approaches for control. J. 
Ind. Microbiol. Biotechnol. 32, 309–318. 
Politeo, O., Juki, M., Milo, M., 2006. Chemical composition and antioxidant activity of 
essential oils of twelve spice plants. Croat. Chem. Acta 79, 545–552. 
Prabhakar, K., Kumar, L.S., Rajendran, S., Chandrasekaran, M., Bhaskar, K., Sajit 
Khan, A.K., 2008. Antifungal activity of plant extracts against Candida species 
from oral lesions. Indian J. Pharm. Sci. 70, 801–803. 
Proença da Cunha, A., Silva, A.P., Roque, O.R., 2012. Plantas e produtos vegetais em 
Fitoterapia, 4oEdição - ed. Lisboa. 
Proença da Cunha, A., Teixeira, F., Silva, A.P., Roque, O.R., 2010. Plantas na 
terapêutica: farmacologia e ensaios clinicos, 2oEdição ed. Lisboa. 
Qader, M.K., Khalid, N.S., Saadullah, A.A.M., 2013. Screening of some plant extracts 
for antifungal activity against Candida species. Int. J. Microbiol. Immunol. Res. 1, 
65–67. 
Rajeh, M.A.B., Zuraini, Z., Sasidharan, S., Latha, L.Y., Amutha, S., 2010. Assessment 
of Euphorbia hirta L. leaf, flower, stem and root extracts for their antibacterial and 
antifungal activity and brine shrimp lethality. Molecules 15, 6008–6018.  
Raman, S.B., Nguyen, M.H., Cheng, S., Badrane, H., Iczkowski, K.A., Wegener, M., 
Gaffen, S.L., Mitchell, A.P., Clancy, C.J., 2013. A competitive infection model of 
hematogenously disseminated candidiasis in mice redefines the role of Candida 
albicans IRS4 in pathogenesis. Infect. Immun. 81, 1430–1438. 
Rana, I.S., Rana, A.S., Rajak, R.C., 2011. Evaluation of antifungal activity in essential 
oil of the Syzygium aromaticum (L.) by extration, purification and analysis of its 
main component eugenol. Brazilian J. Microbiol. 42, 1269–1277. 
Ren, B., Xia, B., Li, W., Wu, J., Zhang, H., 2009. Two novel phenolic compounds from 
Stenoloma chusanum and their antifungal activity. Chem. Nat. Compd. 45, 182–
186. 
Rice-Evans, C.A., Miller, N.J., Paganga, G., 1996. Structure-antioxidant activity 
relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 20, 933–
956. 
Robbins, R.J., 2003. Phenolic acids in foods: an overview of analytical methodology. J. 
Agric. Food Chem. 51, 2866–2887.  
Rose, J., 1999. Herbal and nutritional support for the immune system. Clin. Nutr. 
Insights 6, 1–4. 
Rubió, L., Motilva, M.-J., Romero, M.-P., 2013. Recent advances in biologically active 
compounds in herbs and spices: a review of the most effective antioxidant and anti-
inflammatory active principles. Crit. Rev. Food Sci. Nutr. 53, 943–953.  
Saeed, S., Tariq, P., 2007. Antimicrobial activities of Emblica officinalis and 
Coriandrum sativum against gram positive bacteria and Candida albicans. 
Pakistan J. Bot. 39, 913–917. 
Safaei-Ghomi, J., Ahd, A.A., 2010. Antimicrobial and antifungal properties of the 
essential oil and methanol extracts of Eucalyptus largiflorens and Eucalyptus 
intertexta. Pharmacogn. Mag. 6, 172–175. 
Saleem, M., Nazir, M., Ali, M.S., Hussain, H., Lee, Y.S., Riaz, N., Jabbar, A., 2010. 
Antimicrobial natural products: an update on future antibiotic drug candidates. Nat. 
Prod. Rep. 27, 238–254.  
Sangamwar, A.T., Deshpande, U.D., Pekamwar, S.S., 2008. Antifungals: need to search 
for a new molecular target. Indian J. Pharm. Sci. 70, 423–430. 
Sanglard, D., 2002. Resistance of human fungal pathogens to antifungal drugs. Curr. 
Opin. Microbiol. 5, 379–385. 
Sanglard, D., Odds, F.C., 2002. Reviews resistance of Candida species to antifungal 
agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2, 
73–85. 
Santos-Buelga, C., Gonzalez-Manzano, S., Dueñas, M., Gonzalez-Paramas, A.M., 2012. 
Extraction and isolation of phenolic compounds. Methods Mol. Biol. 864, 427–
464. 
Sardi, J.C.O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A.M., Giannini, M.J.S.M., 
2013. Candida species: current epidemiology, pathogenicity, biofilm formation, 
natural antifungal products and new therapeutic options. J. Med. Microbiol. 62, 
10–24.  
Sertel, S., Fu, Y., Zu, Y., Rebacz, B., Konkimalla, B., Plinkert, P.K., Krämer, A., 
Gertsch, J., Efferth, T., 2011. Molecular docking and pharmacogenomics of Vinca 
alkaloids and their monomeric precursors, vindoline and catharanthine. Biochem. 
Pharmacol. 81, 723–735. 
Shamim, S., Ahmed, S.W., Azhar, I., 2004. Antifungal activity of Allium, Aloe, and 
Solanum species. Arch. Physiol. Biochem. 42, 491–498.  
Sher, A., 2009. Antimicrobial activity of natural products from medicinal plants. Gomal 
J. Med. Sci. 7, 72–78. 
Shojaii, A., Fard, M.A., 2012. Review of pharmacological properties and chemical 
constituents of Pimpinella anisum. Int. Sch. Res. Netw. - ISRN Pharm. 2012, 1–8.  
Siler, B., Zivković, S., Banjanac, T., Cvetković, J., Živković, J.N., Cirić, A., Soković, 
M., Mišić, D., 2014. Centauries as underestimated food additives: antioxidant and 
antimicrobial potential. Food Chem. 147, 367–376.  
Silva, F., Ferreira, S., Duarte, A., Mendonça, D.I., Domingues, F.C., 2011. Antifungal 
activity of Coriandrum sativum essential oil, its mode of action against Candida 
species and potential synergism with amphotericin B. Phytomedicine 19, 42–47.  
Silva, G. de S., 2012. Study of the antimicrobial activity of the medicinal plant extracts 
against clinical isolates of Candida species. State University of Paraíba. 
Silva, N.C.C., Fernandes Júnior, A., 2010. Biological properties of medicinal plants: a 
review of their antimicrobial activity. J. Venom. Anim. Toxins Incl. Trop. Dis. 16, 
402–413. 
Silva, S., Henriques, M., Hayes, A., Oliveira, R., Azeredo, J., Williams, D.W., 2011. 
Candida glabrata and Candida albicans co-infection of an in vitro oral epithelium. 
J. oral Pathol. Med. 40, 421–427. 
Singh, A., Duggal, S., Kaur, N., Singh, J., 2010. Berberine: Alkaloid with wide 
spectrum of pharmacological activities. J. Nat. Prod. 3, 64–75. 
Singh, R.P., Sharad, S., Kapur, S., 2004. Free radicals and oxidative stress in 
neurodegenerative diseases: relevance of dietary antioxidants. J. Indian Acad. Clin. 
Med. 5, 218–225. 
Sobel, J.D., 2007. Vulvovaginal candidosis. Lancet 369, 1961–1971. 
Souza, N.A.B., Lima, E. de O., Guedes, D.N., Pereira, F.D.O., Souza, E.L. de, Sousa, 
F.B., 2010. Efficacy of Origanum essential oils for inhibition of potentially 
pathogenic fungi. Brazilian J. Pharm. Sci. 46, 499–508. 
Sule, A., Ahmed, Q.U., Latip, J., Samah, O.A., Omar, M.N., Umar, A., Dogarai, B.B.S., 
2012. Antifungal activity of Andrographis paniculata extracts and active principles 
against skin pathogenic fungal strains in vitro. Pharm. Biol. 50, 850–856.  
Sullivan, D.J., Moran, G.P., Pinjon, E., Almosaid, A., Stokes, C., Vaughan, C., 
Coleman, D.C., 2004. Comparison of the epidemiology, drug resistance 
mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS 
Yeast Res. 4, 369–376. 
Sun, S., Lou, H., Gao, Y., Fan, P., Ma, B., Ge, W., Wang, X., 2004. Liquid 
chromatography-tandem mass spectrometric method for the analysis of fluconazole 
and evaluation of the impact of phenolic compounds on the concentration of 
fluconazole in Candida albicans. J. Pharm. Biomed. Anal. 34, 1117–1124.  
Tarry, W., Fisher, M., Shen, S., Mawhinney, M., 2005. Candida albicans: the estrogen 
target for vaginal colonization. J. Surg. Res. 129, 278–282.  
Tharkar, P.R., Tatiya, A.U., Shinde, P.R., Surana, S.J., Patil, U.K., 2010. Antifungal 
activity of Glycyrrhiza glabra Linn. and Emblica officinalis Gaertn. by direct 
bioautography method. Int. J. PharmTech Res. 2, 1547–1549. 
Thirach, S., Tragoolpua, K., Punjaisee, S., Jatisatienr, C., Kharmwan, C., Kunyanone, 
N., 2003. Antifungal activity of some medicinal plant extracts against Candida 
albicans and Cryptococcus neoformans. Acta Hortic. 597, 217–221. 
Timothy, S.Y., Wazis, C.H., Adati, R.G., Maspalma, I.D., 2012. Antifungal activity of 
aqueous and ethanolic leaf extracts of Cassia alata Linn. J. Appl. Pharm. Sci. 02, 
182–185.  
Tintino, S.R., Souza, C.E.S., Guedes, G.M.M., Costa, J.I. V., Duarte, F.M., Chaves, 
M.C.O., Silva, V.A., Pessôa, H.L.F., Lima, M.A., Garcia, C.A., Coutinho, H.D.M., 
2014. Modulatory antimicrobial activity of Piper arboreum extracts. Acta Bot. 
Croat. 73, 281–289. 
Tomczykowa, M., Tomczyk, M., Jakoniuk, P., Tryniszewska, E., 2008. Antimicrobial 
and antifungal activities of the extracts and essential oils of Bidens tripartita. Folia 
Histochem. Cytobiol. 46, 389–393.  
Touré, A., Bahi, C., Ouattara, K., Djama, J.A., Coulibaly, A., 2011. Phytochemical 
screening and in vitro antifungal activities of extracts of leaves of Morinda 
morindoides (Morinda, Rubiaceae). J. Med. Plants Res. 5, 6780–6786.  
Tsai, P.-W., Chen, Y.-T., Hsu, P.-C., Lan, C.-Y., 2013. Study of Candida albicans and 
its interactions with the host: a mini review. BioMedicine 3, 51–64.  
Tsuzuki, J.K., Svidzinski, T.I.E., Shinobu, C.S., Silva, L.F.A., Rodrigues-Filho, E., 
Cortez, D.A.G., Ferreira, I.C.P., 2007. Antifungal activity of the extracts and 
saponins from Sapindus saponaria L. Ann. Brazilian Acad. Sci. 79, 577–583. 
Unver, A., Arslan, D., Cetynkaya, Z., Ozcan, M.M., 2008. Antimycotic activity of 
methanol extracts of sage (Salvia officinalis L.), laurel (Laurus nobilis L.) and 
thyme (Thymbra spicata L.). J. Essent. Oil Bear. Plants 11, 90–95. 
Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T.D., Mazur, M., Telser, J., 2007. Free 
radicals and antioxidants in normal physiological functions and human disease. Int. 
J. Biochem. Cell Biol. 39, 44–84. 
Vázquez-González, D., Perusquía-Ortiz, A.M., Hundeiker, M., Bonifaz, A., 2013. 
Opportunistic yeast infections: candidiasis, cryptococcosis, trichosporonosis and 
geotrichosis. J. Ger. Soc. Dermatology 11, 381–394. 
Volleková, A., Kost’álová, D., Kettmann, V., Tóth, J., 2003. Antifungal activity of 
Mahonia aquifolium extract and its major protoberberine alkaloids. Phyther. Res. 
17, 834–837. 
Wächtler, B., Citiulo, F., Jablonowski, N., Förster, S., Dalle, F., Schaller, M., Wilson, 
D., Hube, B., 2012. Candida albicans-epithelial interactions: dissecting the roles of 
active penetration, induced endocytosis and host factors on the infection process. 
PLoS One 7, 1–10.  
Walch, S.G., Tinzoh, L.N., Zimmermann, B.F., Stühlinger, W., Lachenmeier, D.W., 
2011. Antioxidant capacity and polyphenolic composition as quality indicators for 
aqueous infusions of Salvia officinalis L. (sage tea). Front. Pharmacol. 2, 1-6. 
Waldorf, A.R., Polak, A., 1983. Mechanisms of action of 5-fluorocytosine. Antimicrob. 
Agents Chemother. 23, 79–85. 
Wang, J., Lou, J., Luo, C., Zhou, L., Wang, M., Wang, L., 2012. Phenolic compounds 
from Halimodendron halodendron (Pall.) Voss and their antimicrobial and 
antioxidant activities. Int. J. Mol. Sci. 13, 11349–11364. 
Webster, D., Taschereau, P., Belland, R.J., Sand, C., Rennie, R.P., 2008. Antifungal 
activity of medicinal plant extracts; preliminary screening studies. J. 
Ethnopharmacol. 115, 140–146.  
Westwater, C., Schofield, D.A., Nicholas, P.J., Paulling, E.E., Balish, E., 2007. Candida 
glabrata and Candida albicans; dissimilar tissue tropism and infectivity in a 
gnotobiotic model of mucosal candidiasis. FEMS Immunol. Med. Microbiol. 51, 
134–139. 
White, T.C., Holleman, S., Dy, F., Laurence, F., Stevens, D.A., Mirels, L.F., 2002. 
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. 
Agents Chemother. 46, 1704–1713. 
White, T.C., Marr, K.A., Bowden, R.A., 1998. Clinical, cellular, and molecular factors 
that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11, 382–402. 
Wojdylo, A., Oszmianski, J., Czemerys, R., 2007. Antioxidant activity and phenolic 
compounds in 32 selected herbs. Food Chem. 105, 940–949.  
Wong, K.S., Tsang, W.K.P., 2009. In vitro antifungal activity of the aqueous extract of 
Scutellatia baicalensis Georgi root against Candida albicans. Int. J. Antimicrob. 
Agents 34, 283–284. 
Wyk, C. Van, Botha, F.S., Steenkamp, V., 2009. In vitro antimicrobial activity of 
medicinal plants against oral Candida albicans isolates. Int. J. Biomed. Pharm. Sci. 
3, 26–30. 
Xie, Q., Johnson, B.R., Wenckus, C.S., Fayad, M.I., Wu, C.D., 2012. Efficacy of 
berberine, an antimicrobial plant alkaloid, as an endodontic irrigant against a 
mixed-culture biofilm in an in vitro tooth model. J. Endod. 38, 1114–1117. 
Yang, S.W., Ubillas, R., McAlpine, J., Stafford, A, Ecker, D.M., Talbot, M.K., Rogers, 
B., 2001. Three new phenolic compounds from a manipulated plant cell culture, 
Mirabilis jalapa. J. Nat. Prod. 64, 313–317. 
Yazdani, D.M., Rezazadeh, S., Amin, G., Abidin, M.Z., Shahnazi, S., Jamalifar, H., 
2009. Antifungal activity of dried extracts of anise (Pimpinella anisum L.) and star 
anise (Illicium verum Hook.) against dermatophyte and saprophyte fungi. J. Med. 
Plants 8, 24–29. 
Zhu, X.F., Zhang, H.X., Lo, R., 2005. Antifungal activity of Cynara scolymus L. 
extracts. Fitoterapia 76, 108–111. 
 
 
Table 1. Activity of acetone extracts against Candida species 
 
MIC - Minimum inhibitory concentration. 
 
Plant source Candida species MIC References 
Combretum albopunctatum  C. albicans 0.64 mg/mL (Masoko et al., 2010) 
Combretum imberbe C. albicans 2.5 mg/mL (Masoko et al., 2010) 
Combretum nelsonii C. albicans 0.04 mg/mL (Masoko et al., 2010) 
Origanum vulgare C. albicans 5 mg/mL (Ličina et al., 2013) 
Paullinia cupana C. albicans 250 µm/mL (Basile et al., 2013) 
Sclerocarya birrea C. parapsilosis 0.32 mg/mL (Masoko et al., 2008) 
Terminalia sericea C. albicans 0.64 mg/mL (Masoko et al., 2010) 
Table 2. Activity of aqueous extracts against Candida species 
Plant source Candida species MIC  References 
Acorus calamus 
C. albicans 12.5 mg/mL 
(Webster et 
al., 2008) 
C. krusei 12.5 mg/mL 
C. lusitaniae 12.5 mg/mL 
C. parapsilosis 12.5 mg/mL 
Adiantum capillus 
veneris C. albicans 1 mg/mL




0.2 mg/mL (Shamim et al., 2004) 
100 mg/mL* (Fei et al., 2008) 
1 mg/mL* (Pathak, 2012) 
C. dublinensis 1 mg/mL* (Pathak, 2012) 
C. grabrata 
0.2 mg/mL (Shamim et al., 2004) 
1 mg/mL* (Pathak, 2012) 
C. krusei 
100 mg/mL* (Fei et al., 2008) 
1 mg/mL* (Pathak, 2012) 
C. tropicalis 
0.2 mg/mL (Shamim et al., 2004) 
100 mg/mL* (Fei et al., 2008) 
1 mg/mL* (Pathak, 2012) 
Alnus viridis 
C. albicans 12.5 mg/mL 
(Webster et 
al., 2008) 
C. glabrata 25 mg/mL 
C. krusei 0.2 mg/mL 
C. lusitaniae 6 mg/mL 
C. parapsilosis 25 mg/mL 
C. tropicalis 3 mg/mL 
Aloe barbadensis 
C. albicans 1 mg/mL (Shamim et 
al., 2004) C. grabrata 1 mg/mL C. tropicalis 0.2 mg/mL 
Aloe excelsa 
C. albicans 1 mg/mL (Coopoosamy 
and Magwa, 
2007) C. tropicalis 0.2 mg/mL 
Arbutus unedo C. albicans 10 mg/mL* (Dib et al., 2010) 
Arctium minus 
C. albicans 12.5 mg/mL 
(Lubian et al., 
2010) 
C. dubliniensis 12.5 mg/mL 
C. glabrata 12.5 mg/mL 
C. krusei 12.5 mg/mL 
C. stellatoideia 12.5 mg/mL 
C. tropicalis 25 mg/mL 12.5 mg/mL 
Artemisia campestris 
C. glabrata 25 mg/mL 
(Webster et 
al., 2008) 
C. krusei 50 mg/mL 
C. lusitaniae 25 mg/mL 
C. parapsilosis 50 mg/mL 
C. tropicalis 25 mg/mL 
Artemisia frigida 
C. glabrata 0.4 mg/mL 
(Webster et 
al., 2008) 
C. krusei 6 mg/mL 
C. lusitaniae 12.5 mg/mL 
C. parapsilosis 50 mg/mL 
C. tropicalis 6 mg/mL 
Azadirachta indica 
C. albicans 1 mg/mL* 
(Pathak, 
2012) 
C. dublinensis 1 mg/mL* 
C. glabrata 1 mg/mL* 
C. krusei 1 mg/mL* 
C. tropicalis 1 mg/mL* 
Betula alleghaniensis 
C. albicans 0.8 mg/mL 
(Webster et 
al., 2008) 
C. glabrata 0.05 mg/mL 
C. krusei 0.4 mg/mL 
C. lusitaniae 0.4 mg/mL 
C. parapsilosis 3 mg/mL 0.05 mg/mL 
C. tropicalis 6 mg/mL 
Brucea javanica 
C. albicans 50 mg/mL 
(Nordin et al., 
2013) 
C. dubliniensis 3.13 mg/mL 
C. glabrata 25 mg/mL 
C. krusei 50 mg/mL 
C. lusitaniae 25 mg/mL 
C. parapsilosis 25 mg/mL 
C. tropicalis 50 mg/mL 
Cassia alata C. albicans 26.90 mg (Timothy et al., 2012) 
Camellia sinensis C. albicans 10 mg/mL* (Doddanna et al., 2013) 
Cinnamomum sp. 
C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 










C. glabrata 0.025 mg/mL 
C. krusei 0.2 mg/mL 
C. lusitaniae 0.05 mg/mL 
C. parapsilosis 0.4 mg/mL 0.1 mg/mL 
C. tropicalis 1.6 mg/mL 
Eucalyptus sideroxylon C. albicans 400 mg/mL* (Ashour, 2008) 
Eucalyptus torquata C. albicans 400 mg/mL* (Ashour, 2008) 
Fragaria virginiana 







C. lusitaniae 0.1 mg/mL 
C. parapsilosis 0.2 mg/mL 
C. tropicalis 0.8 mg/mL 






subsp. pilifer C. albicans 7.00 mg/mL 
(Džamić et 
al., 2013) 
Lonicera japonica C. albicans Viability (%): 81.48 
(Wong and 
Tsang, 2009) 





Morinda citrifolia C. albicans 40 mg/mL (Jainkittivong et al., 2009) 
Morinda morindoides C. albicans 62.50 mg/mL (Touré et al., 2011) 
Murraya koenigii 
C. albicans 1 mg/mL* 
(Pathak, 
2012) 
C. dublinensis 1 mg/mL* 
C. glabrata 1 mg/mL* 
C. krusei 1 mg/mL* 
C. tropicalis 1 mg/mL* 
Ocimum sanctum C. glabrata 1 mg/mL* (Pathak, 2012) 
Origanum vulgare C. albicans 
200 mg/mL* (Abdul et al., 2012) 
20 mg/mL (Ličina et al., 2013) 




C. albicans 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Populus tremuloides C. albicans 1.6 mg/mL (Webster et 
C. glabrata 0.025 mg/mL al., 2008) 
C. krusei 0.2 mg/mL 
C. lusitaniae 0.2 mg/mL 
C. parapsilosis 0.4 mg/mL 
C. tropicalis 1.6 mg/mL 
Punica granatum 
C. albicans 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
Quercus infectoria 
C. albicans 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Rhus angustifolia 
C. albicans 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Ribes nigrum 
C. glabrata 3.85 mg/mL 
(Krisch et al., 
2008) 
C. inconspicua 2.82 mg/mL 
C. lipolytica 5.15 mg/mL 
C. norvegica 3.62 mg/mL 
C. parapsilosis 2.76 mg/mL 
C. tropicalis 3.75 mg/mL 
C. zeylanoides 1.83 mg/mL 
Rosmarinus officinalis C. albicans 300 mg/mL* (Abdul et al., 2012) 
Salvia officinalis 




C. parapsilosis 2.5 mg/mL (Martins et al., 2015) 
C. tropicalis 1.25 mg/mL (Martins et al., 2015) 
Sapindus saponaria C. parapsilosis 0.16 mg/mL (Tsuzuki et al., 2007) 
Scutellaria baicalensis C. albicans 2.5 mg/mL (Wong and Tsang, 2009) 5 mg/mL 
Solanum nigrum 
C. albicans 0.2 mg/mL (Shamim et 
al., 2004) C. grabrata 1 mg/mL C. tropicalis 0.2 mg/mL 
Solidago gigantean 
C. albicans 0.8 mg/mL 
(Webster et 
al., 2008) 
C. glabrata 0.1 mg/mL 
C. krusei 0.8 mg/mL 
C. lusitaniae 1.6 mg/mL 
C. tropicalis 12.5 mg/mL 
Sonneratia alba C. albicans 0.25 mg/mL (Kaewpiboon et al., 2012) 
Sonneratia caseolaris C. albicans 0.125 mg/mL (Kaewpiboon et al., 2012) 
Syzygium aromaticum 
C. albicans 0.782 mg/mL 
(Kim and 
Lee, 2012) 
C. glabrata 0.025 mg/mL 
C. krusei 0.098 mg/mL  
C. tropicalis 0.003125 mg/mL 
Thymus kotschyana 
C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Thymus vulgaris C. albicans 300 mg/mL* (Abdul et al., 2012) 
Zingiber officinalis 
C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 




Table 3. Activity of ethanolic extracts against Candida species 
Plant source Candida species MIC References 
Achillea biebersteinii C. albicans 100 mg/mL (Hassawi and Kharma, 2006) 
Achillea fragantissima C. albicans 150 mg/mL (Hassawi and Kharma, 2006) 
Acorus calamus C. albicans 28.80 mg/mL (Thirach et al., 2003) 
Adiantum capillus veneris C. albicans 1 mg/mL* (Ishaq et al., 2014) 
Allium cepa C. albicans 10 mg/mL* (Doddanna et al., 2013) 
Allium sativum C. albicans 1 mg/mL* (Joe et al., 2009) 
Allium sativum 
C. albicans 0.2 mg/mL (Shamim et al., 
2004) C. grabrata 0.2 mg/mL C. tropicalis 0.2 mg/mL 
Aloe barbadensis 
C. albicans 1 mg/mL (Shamim et al., 
2004) C. grabrata 1 mg/mL C. tropicalis 0.2 mg/mL 
Aloe excelsa C. albicans 1 mg/mL (Coopoosamy and Magwa, 2007) C. tropicalis 0.2 mg/mL 
Aloe vera C. albicans 10 mg/mL* (Doddanna et al., 2013) 
Andrographis paniculata C. albicans Viability: 103.85% 
(Wong and Tsang, 
2009) 
Anthemis pseudocotula C. albicans 150 mg/mL (Hassawi and Kharma, 2006) 
Artemisia herba-alba C. albicans 100 mg/mL (Hassawi and Kharma, 2006) 
Ballota undulate C. albicans 25 mg/mL (Hashem, 2011) 
Camellia sinensis C. albicans 10 mg/mL* (Doddanna et al., 2013) 
Capparis spinosa C. albicans 100 mg/mL* (Mandeel and Taha, 2005) 
Capsicum annum C. albicans 17.5 mg/mL (Ertürk, 2006) 
Cassia alata C. albicans 5.60 mg (Timothy et al., 2012) 
Cassia siamea 
C. albicans 100 mg/mL 
(Prabhakar et al., 
2008) 
C. glabrata 100 mg/mL 
C. guilliermondii 100 mg/mL 
C. krusei 100 mg/mL 
C. parapsilosis 100 mg/mL 
C. tropicalis 100 mg/mL 
Caulerpa scalpelliformis 
C. albicans 100 mg/mL 
(Prabhakar et al., 
2008) 
C. glabrata 100 mg/mL 
C. guilliermondii 100 mg/mL 
C. krusei 100 mg/mL 
C. parapsilosis 100 mg/mL 
C. tropicalis 100 mg/mL 
Cinnamomum sp. 
C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Cleome amplyocarpa C. albicans 75 mg/mL (Hashem, 2011) 
Colutea arborescens C. albicans 12.5 mg/mL (Ertürk, 2006) 
Convolvulus arvensis C. albicans 100 mg/mL* (Mandeel and Taha, 2005) 
Convolvulus arvensis C. albicans 150 mg/mL (Hassawi and Kharma, 2006) 
Coscinium fenestratum C. albicans 0.5 mg/mL (Kaewpiboon et al., 2012) 
Crataegus oxyacantha C. albicans 10 mg/mL* (Kostić et al., 2012) 
Cressa cretica C. albicans 100 mg/mL* (Mandeel and Taha, 2005) 
Cuminum cyminum C. albicans 15 mg/mL (Ertürk, 2006) 
Cynara scolymus C. albicans 12.5 mg/mL 12.5 mg/mL (Zhu et al., 2005) C. lusitaniae 
Dianthus coryophyllum C. albicans 20 mg/mL (Ertürk, 2006) 
Emex spinosa C. albicans 100 mg/mL* (Mandeel and Taha, 2005) 
Erica arborea C. albicans 2.5 mg/mL (Ertürk, 2006) 
Eugenia caryophyllus C. albicans 17.41 mg/mL (Thirach et al., 2003) 
Eugenia uniflora C. krusei 0.25 mg/mL (Correa-Royero et al., 2010) 
Fagonia indica C. albicans 100 mg/mL* (Mandeel and Taha, 2005) 
Fraxinus rhynchophylla C. albicans Viability: 77.56% 
(Wong and Tsang, 
2009) 
Funtumia elastica C. albicans 100 mg/mL* (Adekunle and Ikumapayi, 2006) 
Glycyrrhiza glabra 
C. albicans 1 mg/mL 
(Fatima et al., 
2009) 
C. krusei 2 mg/mL 
C. nerformans 0.5 mg/mL 
C. pseudotropicalis 1 mg/mL 
Heliotropium 
curassavicum C. albicans 100 mg/mL
* (Mandeel and Taha, 2005) 
Illicium verum C. albicans 16 mg/mL (Yazdani et al., 2009) 
Isatis indigotica C. albicans Viability: 94.05% 
(Wong and Tsang, 
2009) 
Juniperus oxycedrus C. albicans 5 mg/mL (Ertürk, 2006) 
Lantana fucata C. krusei 0.5 mg/mL (Correa-Royero et al., 2010) 
Laurus nobilis C. albicans 5 mg/mL (Ertürk, 2006) 
Mahonia aquifolium C. tropicalis 1000 µg/mL (Volleková et al., 
2003) 
Mallotus oppositifolius C. albicans 100 mg/mL* (Adekunle and Ikumapayi, 2006) 
Melissa officinalis C. albicans 25 mg/mL (Ertürk, 2006) 
Mentha piperita C. albicans 5 mg/mL (Ertürk, 2006) 
Mentha piperita C. albicans 10 mg/mL* (Doddanna et al., 2013) 
Morinda morindoides C. albicans 31.25 mg/mL (Touré et al., 2011) 
Morinda royoc C. krusei 0.25 mg/mL (Correa-Royero et al., 2010) 
Murraya koenigii C. albicans 10 mg/mL* (Doddanna et al., 2013) 




C. albicans 500 mg/mL 
(Prabhakar et al., 
2008) 
C. glabrata 500 mg/mL 
C. guilliermondii 500 mg/mL 
C. krusei 500 mg/mL 
C. parapsilosis 500 mg/mL 
C. tropicalis 500 mg/mL 
Origanum vulgare C. albicans 5 mg/mL (Ličina et al., 2013) 10 mg/mL 
Paullinia cupana C. albicans 0.5 mg/mL (Basile et al., 2013) 
Pimpinella anisum 
C. albicans 19 %, v/v 
(Kosalec et al., 
2005) 
C. krusei 20 %, v/v 
C. parapsilosis 18 %, v/v 
C. pseudotropicalis 17 %, v/v 
C. tropicalis 18 %, v/v 
Piper nigrum C. albicans 12.5 mg/mL (Ertürk, 2006) 1.5 mg/mL* (Joe et al., 2009) 
Piper regnellii 
C. albicans 0.125 mg/mL (Pessini et al., 
2005) C. krusei 0.5 mg/mL C. parapsilosis 0.5 mg/mL 
Plantago lanceolata 




C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Pluchea ovalis C. albicans 100 mg/mL* (Mandeel and Taha, 2005) 
Punica granatum 
C. albicans 0.25 mg/mL 
(Anibal et al., 
2013) 
C. dubliniensis 0.25 mg/mL 
C. glabrata 0.25 mg/mL 
C. guilliermondii 0.125 mg/mL 
C. krusei 0.125 mg/mL 
C. lusitaniae 0.125 mg/mL 
C. parapsilosis 0.125 mg/mL 
C. rugosa 0.125 mg/mL 
C. tropicalis 0.25 mg/mL 
C. utilis 0.25 mg/mL 
Punica granatum 
C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Quercus infectoria 
C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Rhus angustifolia 
C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Rhus coriaria C. albicans 15 mg/mL (Ertürk, 2006) 
Sargassum wightii 
C. albicans 100 mg/mL 
(Prabhakar et al., 
2008) 
C. glabrata 100 mg/mL 
C. guilliermondii 100 mg/mL 
C. krusei 100 mg/mL 
C. parapsilosis 100 mg/mL 
C. tropicalis 100 mg/mL 
Sclerocarya birrea C. parapsilosis 0.21 mg/mL (Masoko et al., 2008) 
Solanum nigrum 
C. albicans 0.2 mg/mL (Shamim et al., 
2004) C. grabrata 1 mg/mL C. tropicalis 0.2 mg/mL 
Syzygium jambolanum 
C. albicans 100 mg/mL 
(Prabhakar et al., 
2008) 
C. glabrata 100 mg/mL 
C. guilliermondii 100 mg/mL 
C. krusei 100 mg/mL 
C. parapsilosis 100 mg/mL 
C. tropicalis 100 mg/mL 
Tamarix arabica C. albicans 100 mg/mL* (Mandeel and Taha, 2005) 
Thymus kotschyana 
C. albicanus 200 mg/mL* 
(Qader et al., 
2013) 
C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
Zingiber officinale C. albicans 1 mg/mL* (Joe et al., 2009) 
Zingiber officinalis C. albicanus 200 mg/mL
* (Qader et al., 
2013) C. dublicans 200 mg/mL* 
C. glabrata 200 mg/mL* 
C. krusei 200 mg/mL* 
C. tropicalis 200 mg/mL* 
*Concentration used to evaluate antifungal activity by disc diffusion. MIC - Minimum 
inhibitory concentration. 
 
Table 4. Activity of methanol-dichloromethane extracts against Candida species 
Plant source Species MIC References 
Aframomum citratum 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 4.68 mg/mL 
C. guilliermondii 3.12 mg/mL 
C. krusei 0.39 mg/mL 
C. lusitaniae 0.78 mg/mL 
C. parapsilosis 6.25 mg/mL 
C. tropicalis 6.25 mg/mL 
Aframomum melegueta 
C. albicans 6.25 mg/mL 
(Dzoyem et 
al., 2014) 
C. guilliermondii 1.56 mg/mL 
C. krusei 6.25 mg/mL 
C. lusitaniae 3.12 mg/mL 
C. parapsilosis 6.25 mg/mL 
C. tropicalis 1.56 mg/mL 
Andrographis paniculata* 
C. albicans 0.1 mg/mL (Sule et al., 
2012) C. krusei 0.25 mg/mL C. tropicalis 0.1 mg/mL 
Bielschmiedia cinnamomea 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 6.25 mg/mL 
C. guilliermondii 6.25 mg/mL 
C. lusitaniae 3.12 mg/mL 
C. tropicalis 3.12 mg/mL 
Cinnamomum zeylanicum 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 3.12 mg/mL 
C. guilliermondii 0.78 mg/mL 
C. krusei 0.78 mg/mL 
C. lusitaniae 0.78 mg/mL 
C. parapsilosis 3.12 mg/mL 
C. tropicalis 0.097 mg/mL 
Dichrostachys glomerata 
C. albicans 0.39 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 3.12 mg/mL 
C. guilliermondii 3.12 mg/mL 
C. krusei 3.12 mg/mL 
C. lusitaniae 0.39 mg/mL 
C. parapsilosis 6.25 mg/mL 
C. tropicalis 3.12 mg/mL 
Diospyros crassiflora 
C. albicans 12.5 mg/mL 
(Dzoyem et 
al., 2007) 
C. glabrata 25 mg/mL 
C. krusei 12.5 mg/mL 
C. tropicalis 12.5 mg/mL 
Dorstenia psilirus 
C. albicans 0.39 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 3.12 mg/mL 
C. guilliermondii 1.56 mg/mL 
C. krusei 3.12 mg/mL 
C. lusitaniae 3.12 mg/mL 
C. parapsilosis 3.12 mg/mL 
C. tropicalis 0.39 mg/mL 
Echinops giganteus 
C. albicans 6.25 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 1.56 mg/mL 
C. guilliermondii 3.12 mg/mL 
C. lusitaniae 6.25 mg/mL 
C. parapsilosis 6.25 mg/mL 
C. tropicalis 6.25 mg/mL 
Fagara leprieurii 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 3.12 mg/mL 
C. krusei 6.25 mg/mL 
C. parapsilosis 6.25 mg/mL 
C. tropicalis 6.25 mg/mL 
Fagara macrophylla 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 3.12 mg/mL 
C. guilliermondii 1.56 mg/mL 
C. krusei 6.25 mg/mL 
C. lusitaniae 1.56 mg/mL 
C. tropicalis 0.39 mg/mL 
Gonzalagunia rosea* C. albicans 2.50 mg/mL (Niño et al., 2007) 
Imperata cylindrical 
C. albicans 6.25 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 3.12 mg/mL 
C. guilliermondii 3.12 mg/mL 
C. krusei 1.56 mg/mL 
C. lusitaniae 3.12 mg/mL 
C. parapsilosis 6.25 mg/mL 
C. tropicalis 3.12 mg/mL 
Liabum asclepiadeum* C. albicans 0.62 mg/mL (Niño et al., 2007) 
Mondia whitei 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. guilliermondii 6.25 mg/mL 
C. lusitaniae 3.12 mg/mL 
C. tropicalis 3.12 mg/mL 
Monodora myristica 
C. albicans 6.25 mg/mL 
(Dzoyem et 
al., 2014) 
C. guilliermondii 3.12 mg/mL 
C. krusei 6.25 mg/mL 
C. lusitaniae 3.12 mg/mL 
C. tropicalis 3.12 mg/mL 
Montanoa* C. albicans 1.25 mg/mL (Niño et al., 2007) 
Olax subscorpioidea 
C. albicans 0.097 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 1.56 mg/mL 
C. guilliermondii 0.78 mg/mL 
C. krusei 1.56 mg/mL 
C. lusitaniae 0.19 mg/mL 
C. parapsilosis 0.39 mg/mL 
C. tropicalis 0.048 mg/mL 
Pentadiplandra brazzeana 
C. albicans 3.12 mg/mL (Dzoyem et 
al., 2014) C. glabrata 6.25 mg/mL
 
C. guilliermondii 6.25 mg/mL 
C. lusitaniae 6.25 mg/mL 
C. tropicalis 1.56 mg/mL 
Piper capense 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. guilliermondii 3.12 mg/mL 
C. krusei 3.12 mg/mL 
C. lusitaniae 1.56 mg/mL 
C. parapsilosis 3.12 mg/mL 
C. tropicalis 0.19 mg/mL 
Piper guineense 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 3.12 mg/mL 
C. lusitaniae 1.56 mg/mL 
C. parapsilosis 6.25 mg/mL 
C. tropicalis 3.12 mg/mL 
Schizozygia caffaeoides* C. albicans 2.5 mg/mL (Kariba et al., 2001) 
Scorodophloeus zenkeri 
C. albicans 2.34 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 4.68 mg/mL 
C. guilliermondii 6.25 mg/mL 
C. krusei 3.90 mg/mL 
C. lusitaniae 2.34 mg/mL 
C. parapsilosis 6.25 mg/mL 
C. tropicalis 4.68 mg/mL 
Solanum melongena C. guilliermondii 6.25 mg/mL
 (Dzoyem et 
al., 2014) C. tropicalis 3.12 mg/mL 
Tetrapleura tretraptera 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 6.25 mg/mL 
C. guilliermondii 3.12 mg/mL 
C. krusei 6.25 mg/mL 
C. lusitaniae 3.12 mg/mL 
C. parapsilosis 3.12 mg/mL 
C. tropicalis 6.25 mg/mL 
Xylopia aethiopica 
C. albicans 3.12 mg/mL 
(Dzoyem et 
al., 2014) 
C. krusei 3.12 mg/Ml 
C. parapsilosis 3.12 mg/mL 
C. tropicalis 3.12 mg/mL 
Xylopia parviflora 
C. albicans 6.25 mg/mL 
(Dzoyem et 
al., 2014) 
C. glabrata 6.25 mg/mL 
C. guilliermondii 3.12 mg/mL 
C. krusei 3.12 mg/mL 
C. lusitaniae 1.56 mg/mL 
C. parapsilosis 3.12 mg/mL 
C. tropicalis 3.12 mg/mL 
*Dichloromethane extracts. MIC - Minimum inhibitory concentration. 
 
 
Table 5. Activity of methanolic extracts against Candida species 
Plant sources Candida species MIC References 
Adiantum capillus veneris C. albicans 1 mg/mL* (Ishaq et al., 2014) 
Anagyris foetida 
C. albicans 12.5 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 25 mg/mL 
C. krusei 12.5 mg/mL 
Andrographis paniculata 
C. albicans 0.2 mg/mL (Sule et al., 
2012) C. krusei 0.2 mg/mL 
C. tropicalis 0.150 mg/mL 
Arrabidaea chica C. albicans 0.5 mg/mL (Höfling et al., 2011) 
Artemisia herba-alba 
C. albicans 6.3 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 25 mg/mL 
C. krusei 12.5 mg/mL 
Caesalpinia pulcherrima C. albicans 0.125 mg/disc* (Parekh and Chanda, 2008) 
Capparis spinosa 
C. albicans 12.5 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 12.5 mg/mL 
C. krusei 12.5 mg/mL 
Cassia fistula 
C. albicans 0.150 mg/mL (Irshad et al., 
2011) C. glabrata 0.1 mg/mL 
C. tropicalis 0.250 mg/mL 
Centaurium erythraea C. albicans 0.1 mg/mL (Siler et al., 2014) 
Centaurium littorale spp. 
uliginosum C. albicans 0.2 mg/mL 
(Siler et al., 
2014) 
Centaurium pulchellum C. albicans 0.4 mg/mL (Siler et al., 2014) 
Centaurium spicatum C. albicans 0.2 mg/mL (Siler et al., 2014) 
Centaurium tenuiflorum C. albicans 0.2 mg/mL (Siler et al., 2014) 
Crossandra 





C. albicans 0.0125 mg/mL (Dzoyem et al., 
2011) C. kefyr 0.025 mg/mL 
C. parapsilosis 0.0125 mg/mL 
Dorstenia turbinata C. albicans 0.039 mg/mL (Ngameni et al., 2009) C. glabrata 0.039 mg/mL 
Ephedra pachyclada C. albicans 0.0005 mg/mL* (Parsaeimehr et al., 2010) 
Ephedra procera C. albicans 0.0005 mg/mL* (Parsaeimehr et 
al., 2010) 
Ephedra strobilacea C. albicans 0.001 mg/mL* (Parsaeimehr et al., 2010) 
Equinops polyceras 
C. albicans 6.3 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 12.5 mg/mL 
C. krusei 3.1 mg/mL 
Eucalyptus intertexta C. albicans 0.0625 mg/mL (Safaei-Ghomi and Ahd, 2010) 
Eucalyptus largiflorens C. albicans 0.0312 mg/mL (Safaei-Ghomi and Ahd, 2010) 
Eucalyptus sideroxylon C. albicans 400 mg/mL* (Ashour, 2008) 
Eucalyptus torquata C. albicans 400 mg/mL* (Ashour, 2008) 
Euphorbia hirta C. albicans 3.13 mg/mL (Rajeh et al., 2010) 
Euphorbia macroclada 




C. glabrata 12.5 mg/mL 25 mg/mL 
C. krusei 12.5 mg/mL 25 mg/mL 
Euphorbia tirucalli C. albicans 0.125 mg/disc* (Parekh and Chanda, 2008) 
Glycyrrhiza glabra C. albicans 0.0005 mg/mL* (Karomi et al., 2012) 
Gonzalagunia rosea C. albicans 1.25 mg/mL (Niño et al., 2007) 
Holarrhena antidysenterica C. tropicalis 0.125 mg/disc* (Parekh and Chanda, 2008) 
Hybiscus sabdariffa C. krusei 25 mg/mL (Darwish and Aburjai, 2011) 
Hypericum trequetrifolium 
C. albicans 12.5 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 25 mg/mL C. krusei 12.5 mg/mL 
Hyssopus officinalis subsp. 
pilifer C. albicans 10 mg/mL 
(Džamić et al., 
2013) 
Laurus nobilis 
C. albicans 0.13 mg/mL 
(Unver et al., 
2008) 
C. glabrata 0.13 mg/mL 
C. holmii 0.16 mg/mL 
C. insane 0.07 mg/mL 
C. krusei 0.07 mg/mL 
C. tropicalis 0.04 mg/mL 
Leiothrix spiralis 
C. albicans 0.5 mg/mL 
(Araújo et al., 
2012) 
C. krusei 0.5 mg/mL 
C. parapsilosis 0.25 mg/mL 
C. tropicalis 1 mg/mL 
Lepidium sativum C. albicans 25 mg/mL (Darwish and Aburjai, 2011) 
Mangifera indica C. albicans 0.125 mg/disc* (Parekh and Chanda, 2008) 
Mentha longifolia 
C. albicans 6.3 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 12.5 mg/mL C. krusei 12.5 mg/mL 
Mesua ferra C. albicans 0.125 mg/disc* (Parekh and Chanda, 2008) 
Mindium laevigatum C. albicans 0.1 mg/mL (Modaressi et al., 2013) 
Montanoa C. albicans 0.62 mg/mL (Niño et al., 2007) 
Munnozia senecionidis C. albicans 2.5 mg/mL (Niño et al., 2007) 
Origanum syriacum 
C. albicans 6.3 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 12.5 mg/mL C. krusei 12.5 mg/mL 
Paeonia rockii C. albicans 0.025 mg/mL (Picerno et al., 2011) 
Phlomis brachydon 
C. albicans 6.3 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 12.5 mg/mL C. krusei 3.1 mg/mL 
Pimpinella anisum 
C. albicans 12.5 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 12.5 mg/mL C. krusei 25 mg/mL 
Pimpinella anisum C. albicans 16 mg/mL (Yazdani et al., 2009) 




Ribes x nidigrolaria 
C. glabrata 2.91 mg/mL 
(Krisch et al., 
2008) 
C. inconspicua 3.33 mg/mL 
C. lipolytica 4.67 mg/mL 
C. norvegica 10.98 mg/mL 
C. parapsilosis 3.56 mg/mL 
C. tropicalis 4.23 mg/mL 
C. zeylanoides 5.68 mg/mL 
Ribes nigrum 
C. guilliermondii 6.13 mg/mL 
(Krisch et al., 
2008) 
C. inconspicua 4.22 mg/mL 
C. parapsilosis 4.41 mg/mL 
C. tropicalis 7.16 mg/mL 
Ribes uva-crispa C. glabrata 4.60 mg/mL (Krisch et al., 2008) C. lipolytica 4.63 mg/mL 
Salvia officinalis C. clus 0.16 mg/mL (Unver et al., 2008) C. tropicalis 0.16 mg/mL 
Saussurea lappa C. albicans 0.125 mg/disc* (Parekh and Chanda, 2008) 
Schistocarpha sinforosi C. albicans 2.5 mg/mL (Niño et al., 
2007) 
Schizozygia caffaeoides C. albicans 10 mg/mL (Kariba et al., 2001) 
Sclerocarya birrea C. parapsilosis 0.32 mg/mL (Masoko et al., 2008) 
Thea sinensis 
C. albicans 6.3 mg/mL (Darwish and 
Aburjai, 2011) C. glabrata 12.5 mg/mL C. krusei 12.5 mg/mL 
Thecacoris annobonae C. albicans 0.3125 mg/mL (Kuete et al., 2010) 
Thymbra spicata 
C. albicans 0.04 mg/mL 
(Unver et al., 
2008) 
C. clus 0.01 mg/mL 
C. glabrata 0.01 mg/mL 
C. krusei 0.01 mg/mL 
C. parapsilosis 0.01 mg/mL 
C. tropicalis 0.01 mg/mL 
Trapa natans C. tropicalis 0.125 mg/disc* (Parekh and Chanda, 2008) 
Trigonella foenum-
graecum 
C. albicans 12.5 mg/mL (Darwish and 
Aburjai, 2011) C. krusei 12.5 mg/mL 
Varthemia iphionoides C. albicans 6.3 mg/mL (Darwish and Aburjai, 2011) 
Verbesina nudipes C. albicans 2.5 mg/mL (Niño et al., 2007) 
Vitex negundo C. albicans 0.125 mg/disc* (Parekh and Chanda, 2008) 
*Concentration used to evaluate antifungal activity by disc diffusion. MIC - Minimum 
inhibitory concentration. 
 
Table 6. Activity of hydroalcoholic extracts against Candida species 





























C. albicans 0.1 mg/mL* 
(Silva, 
2012) 
C. guilhermondii 0.1 mg/mL* 
C. krusei 0.1 mg/mL* 
C. parapsilosis 0.1 mg/mL* 





C. guilhermondii 0.05 mg/mL 
(Silva, 
2012) C. parapsilosis 0.1 mg/mL
* 








(50:50 v/v)  
Punica 
granatum 
C. albicans 0.0039 mg/mL (Endo et al., 
2010) C. parapsilosis 0.0039 mg/mL 
Methanol: water 




(80:20 v/v)  
Castanea 
sativa 
C. albicans 0.625 mg/mL (Barros et 
al., 2013a) C. tropicalis 0.625 mg/mL 
Methanol: water 
(80:20 v/v)  
Cistus 




(80:20 v/v)  
Filipendula 
ulmaria 
C. albicans 0.625 mg/mL (Barros et 
al., 2013a) C. tropicalis 0.155 mg/mL 
Methanol: water 
(80:20 v/v)  
Rosa 
micrantha C. albicans 0.05 mg/mL 
(Barros et 
al., 2013a) 





C. parapsilosis 2.5 mg/mL (Martins et 
al., 2015) C. tropicalis 1.25 mg/mL 
*Concentration used to evaluate antifungal activity by disc diffusion. MIC - Minimum 
inhibitory concentration. 
 
Table 7. Activity of other extracts against Candida species 









Psidium guajava 125 mg/mL 
Syzygium 
aromaticum 62.5 mg/mL 
Diethyl ether  Origanum vulgare C. albicans 5 mg/mL (Ličina et al., 2013) 
Ethyl acetate  
Crossandra 





C. albicans 12.5 mg/mL (Zhu et al., 
2005) C. lusitaniae 12.5 mg/mL 
Hyssopus officinalis 
subsp. Pilifer C. albicans 7.00 mg/mL 
(Džamić et 
al., 2013) 




C. albicans 100 mg/mL (Cardoso et 
al., 2012) C. krusei 100 mg/mL 
Malva sylvestris 
C. albicans 100 mg/mL 
(Cardoso et 
al., 2012) C. krusei 25 mg/mL 
C. tropicalis 100 mg/mL 
Salvia officinalis C. krusei 100 mg/mL (Cardoso et al., 2012) 
MIC - Minimum inhibitory concentration. 
 
Table 8. Activity of phenolics acids against Candida species 
Phenolic acids Source Candida species MIC  References 
Hydroxycinnamic 
acid derivatives 




C. albicans 8 µg/mL (Ozçelik et 




C. albicans 8 µg/mL (Ozçelik et 







C. albicans; C. 
parapsilosis; C. 
glabrata; C. 
tropicalis; C. krusei; 
C. lusitaniae 
820 µg/mLa 







C. albicans; C. 
parapsilosis;  
C. glabrata; C. 
tropicalis; C. krusei; 
C. lusitaniae 
820 µg/mLa 







C. albicans 40 µg/mL 
(Siler et al., 
2014) 
C. albicans; C. 
parapsilosis; C. 
glabrata; C. 
tropicalis; C. krusei; 
C. lusitaniae 
820 µg/mLa 





C. albicans  20 µg/mL 












    
Gallic acid Lythrum C. albicans  2500 µg/mL (Manayi et 
salicaria al., 2013) 











C. glabrata 62 µg/mL 
C. krusei 125 µg/mL 
Commercial 
compound 
C. albicans 8 µg/mL (Ozçelik et 




C. albicans  50 µg/mL 







C. albicans  100 µg/mL 





















C. krusei; C. 
lusitaniae  
690 µg/mLa 





C. albicans  50 µg/mL 





C. albicans  50 µg/mL 







C. albicans  50 µg/mL 


















C. albicans  4 µg/mL 






C. albicans  5 µg/mL 






C. albicans  40 µg/mL 







C. albicans  10 µg/mL 






C. albicans  5 µg/mL 














C. albicans 8 µg/mL (Ozçelik et 
al., 2011) C. parapsilosis 16 µg/mL 
MIC - Minimum inhibitory concentration. aTested concentration and not MIC. b 
Phenolic amides 
 




MIC  References 








C. glabrata  
0.1 µg/ga 
(Kursat et 








C. glabrata  
42.8 µg/ga 
(Kursat et 








C. glabrata  
0.2 µg/ga 
(Kursat et 


































































C. albicans 40 µg/mL 
(Siler et al., 
2014) 
































C. albicans  250 µg/mL 
(Wang et 
al., 2012) 




























2′-O- Mirabilis C. albicans 16-25 µg/mL (Yang et 
MIC- Minimum inhibitory concentration. aCompound concentration in the tested 
extract. 
 





C. albicans 48 µg/mL 
(Yang et 
al., 2001) 



















Table 10. Activity of hydrolyzable tannins, stilbenes and xanthones against Candida 
species 











C. albicans 500 µg/mL (Latte and 
Kolodziej, 
2000) 
C. glabrata 31 µg/mL 





C. glabrata 31 µg/mL (Latte and 
Kolodziej, 





C. glabrata 31 µg/mL (Latte and 
Kolodziej, 





C. albicans 500 µg/mL (Latte and 
Kolodziej, 
2000) 
C. glabrata 31 µg/mL 





C. albicans 500 µg/mL (Latte and 
Kolodziej, 
2000) 
C. glabrata 31 µg/mL 
C. krusei 125 µg/mL 
Punicalagin Punica granatum C. albicans 3.9 µg/mL (Endo et al., 2010) C. parapsilosis 1.9 µg/mL 
Not specified Rhizophora apiculate C. albicans 6250 µg/mL 
(Lim et al., 
2006) 
Stilbenes     
Resveratrol Commercial compound 
C. albicans  16 µg/mL (Sun et al., 2004) 




compound C. albicans  16 µg/mL 
(Sun et al., 
2004) 






C. albicans 62.5 µg/mL 
(Araújo et 
al., 2011) 
C. krusei 15.7 µg/mL 
C. parapsilosis 15.7 µg/mL 
C. tropicalis 31.25 µg/mL 
Mangiferin Commercial compound C. albicans 40 µg/mL 








Proteins	   Lipids	   Carbohydrates	   Chlorophyll	  
Secondary	  
metabolism	  
Alkaloids	   Terpenes	  and	  steroids	  
Phenolic	  
compounds	  






























































Simple	  oxygenated	  xanthones	  
Xanthone	  glycosides	  
Prenylated	  and	  related	  xanthones	  
Xanthonolignoids	  and	  miscellaneous	  
 
Lignins	  
Lignins	  of	  soQwoods	  
Lignins	  of	  hardwoods	  
Lignins	  of	  grasses	  
Figure 2: Main classes and subclasses of phenolic compounds 
